



(86) Date de dépôt PCT/PCT Filing Date: 2004/07/06  
(87) Date publication PCT/PCT Publication Date: 2005/01/27  
(45) Date de délivrance/Issue Date: 2013/10/01  
(85) Entrée phase nationale/National Entry: 2006/01/06  
(86) N° demande PCT/PCT Application No.: US 2004/021569  
(87) N° publication PCT/PCT Publication No.: 2005/007164  
(30) Priorité/Priority: 2003/07/07 (US60/485,436)

(51) Cl.Int./Int.Cl. *C07D 239/54* (2006.01),  
*A61K 31/506* (2006.01), *A61K 31/513* (2006.01),  
*A61P 5/04* (2006.01), *C07D 401/06* (2006.01)


(72) Inventeurs/Inventors:  
ZHU, YUN-FEI, US;  
REGAN, COLLIN, US;  
RUETER, JAIMIE K., US;  
GUO, ZHIQIANG, US;  
CHEN, YONGSHENG, US;  
HUANG, CHARLES Q., US

(73) Propriétaire/Owner:  
NEUROCRINE BIOSCIENCES, INC., US

(74) Agent: OYEN WIGGS GREEN & MUTALA LLP

(54) Titre : DERIVES DE PYRIMIDINE-2,4-DIONE, SERVANT D'ANTAGONISTES AU RECEPTEUR DE L'HORMONE DE LIBERATION DE LA GONADOTROPINE

(54) Title: PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS



(I)

(57) Abrégé/Abstract:

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure formula (I) wherein  $R_{1a}$ ,  $R_{1b}$ ,  $R_{2a}$ ,  $R_{2b}$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$  and



(57) **Abrégé(suite)/Abstract(continued):**

X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number  
**WO 2005/007164 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/513**,  
C07D 239/54, 401/06, A61P 5/02

(74) Agents: **HERMANN, Karl** et al.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).

(21) International Application Number:  
PCT/US2004/021569

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 6 July 2004 (06.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/485,436 7 July 2003 (07.07.2003) US

(71) Applicant (*for all designated States except US*): **NEUROCRINE BIOSCIENCES, INC.** [US/US]; 12790 El Camino Real, San Diego, California 92130 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ZHU, Yun-Fei** [US/US]; 7306 Park Village Road, San Diego, California 92129 (US). **REGAN, Collin** [US/US]; 5046 Collwood Way, #56, San Diego, California 92155 (US). **RUETER, Jaimie, K.** [US/US]; 9022 Westvale Road, San Diego, California 92129 (US). **GUO, Zhiqiang** [CN/US]; 4528 Calle Mar de Armonia, San Diego, California 92130 (US). **CHEN, Yongsheng** [CN/US]; 10510 Clasico Court, San Diego, California 92127 (US). **HUANG, Charles, Q.** [US/US]; 12341 Goldfish Court, San Diego, California 92129 (US).


(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS



(57) Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure formula (I) wherein R<sub>1a</sub>, R<sub>1b</sub>, R<sub>2a</sub>, R<sub>2b</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

WO 2005/007164 A1

## PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS

## STATEMENT OF GOVERNMENT INTEREST

Partial funding of the work described herein was provided by the U.S. Government under Grant No. 1-R43-HD38625 and 2R44-HD38625-02 provided by the National Institutes of Health. The U.S. Government may have certain rights in this invention.

## BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates generally to gonadotropin-releasing hormone (GnRH) receptor antagonists, and to methods of treating disorders by administration of such antagonists to a warm-blooded animal in need thereof.

Description of the Related Art

Gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH), is a decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH<sub>2</sub>) that plays an important role in human reproduction. GnRH is released from the hypothalamus and acts on the pituitary gland to stimulate the biosynthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH released from the pituitary gland is responsible for the regulation of gonadal steroid production in both males and females, while FSH regulates spermatogenesis in males and follicular development in females.

Due to its biological importance, synthetic antagonists and agonists to GnRH have been the focus of considerable attention, particularly in the context of prostate cancer, breast cancer, endometriosis, uterine leiomyoma (fibroids), ovarian cancer, prostatic hyperplasia, assisted reproductive therapy, and precocious puberty

(*The Lancet* 358:1793-1803, 2001; *Mol. Cell. Endo.* 166:9-14, 2000). For example, peptidic GnRH agonists, such as leuprorelin (pGlu-His-Trp-Ser-Tyr-d-Leu-Leu-Arg-Pro-NHEt), have been used to treat such conditions. Such agonists appear to function by binding to the GnRH receptor in the pituitary gonadotropins, thereby inducing the  
5 synthesis and release of gonadotropins. Chronic administration of GnRH agonists depletes gonadotropins and subsequently down-regulates the receptor, resulting in suppression of steroidal hormones after some period of time (*e.g.*, on the order of 2-3 weeks following initiation of chronic administration).

In contrast, GnRH antagonists are believed to suppress gonadotropins  
10 from the onset, and thus have received the most attention over the past two decades. To date, some of the primary obstacles to the clinical use of such antagonists have been their relatively low bioavailability and adverse side effects caused by histamine release. However, several peptidic antagonists with low histamine release properties have been reported, although they still must be delivered via sustained delivery routes (such as  
15 subcutaneous injection or intranasal spray) due to limited bioavailability.


In view of the limitations associated with peptidic GnRH antagonists, a number of nonpeptidic compounds have been proposed. For example, Cho et al. (*J. Med. Chem.* 41:4190-4195, 1998) discloses thieno[2,3-b]pyridin-4-ones for use as GnRH receptor antagonists; U.S. Patent Nos. 5,780,437 and 5,849,764 teach substituted  
20 indoles as GnRH receptor antagonists (as do published PCTs WO 97/21704, 98/55479, 98/55470, 98/55116, 98/55119, 97/21707, 97/21703 and 97/21435); published PCT WO 96/38438 discloses tricyclic diazepines as GnRH receptor antagonists; published PCTs WO97/14682, 97/14697 and 99/09033 disclose quinoline and thienopyridine derivatives as GnRH antagonists; published PCTs WO 97/44037, 97/44041, 97/44321  
25 and 97/44339 teach substituted quinolin-2-ones as GnRH receptor antagonists; and published PCT WO 99/33831 discloses certain phenyl-substituted fused nitrogen-containing bicyclic compounds as GnRH receptor antagonists. Recently published PCTs WO 02/066459 and WO 02/11732 disclose the use of indole derivatives and novel bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists, respectively.  
30 Other recently published PCTs which disclose compounds and their use as GnRH

antagonists include WO 00/69859, WO 01/29044, WO 01/55119, WO 03/013528, WO 03/011870, WO 03/011841, WO 03/011839 and WO 03/011293.

While significant strides have been made in this field, there remains a need in the art for effective small molecule GnRH receptor antagonists. There is also a need for pharmaceutical compositions containing such GnRH receptor antagonists, as well as methods relating to the use thereof to treat, for example, sex-hormone related conditions. The present invention fulfills these needs, and provides other related advantages.

### BRIEF SUMMARY OF THE INVENTION

In brief, this invention is generally directed to gonadotropin-releasing hormone (GnRH) receptor antagonists, as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same. More specifically, the GnRH receptor antagonists of this invention are compounds having the following general structure (I):



(I)

including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein  $R_{1a}$ ,  $R_{1b}$ ,  $R_{2a}$ ,  $R_{2b}$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$  and  $X$  are as defined below.

The GnRH receptor antagonists of this invention have utility over a wide range of therapeutic applications, and may be used to treat a variety of sex-hormone related conditions in both men and women, as well as a mammal in general (also referred to herein as a "subject"). For example, such conditions include endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal

steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrophe pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (*e.g.*, assisted reproductive therapy such as in vitro fertilization). The compounds of this invention are  
5 also useful as an adjunct to treatment of growth hormone deficiency and short stature, and for the treatment of systemic lupus erythematosus. The compounds are also useful in combination with androgens, estrogens, progesterones, and antiestrogens and antiprogestogens for the treatment of endometriosis, fibroids, and in contraception, as well as in combination with an angiotensin-converting enzyme inhibitor, an angiotensin  
10 II-receptor antagonist, or a renin inhibitor for the treatment of uterine fibroids. In addition, the compounds may be used in combination with bisphosphonates and other agents for the treatment and/or prevention of disturbances of calcium, phosphate and bone metabolism, and in combination with estrogens, progesterones and/or androgens for the prevention or treatment of bone loss or hypogonadal symptoms such as hot  
15 flashes during therapy with a GnRH antagonist.

The compounds of the present invention, in addition to their GnRH receptor antagonist activity, possess a reduced interaction with the major metabolic enzymes in the liver, namely the Cytochrome P450 enzymes. This family of enzymes, which includes the subtypes CYP2D6 and CYP3A4, is responsible for the metabolism  
20 of drugs and toxins leading to their disposition from the body. Inhibition of these enzymes can lead to life-threatening conditions where the enzyme is not able to perform this function.


The methods of this invention include administering an effective amount of a GnRH receptor antagonist, preferably in the form of a pharmaceutical composition,  
25 to a mammal in need thereof. Thus, in still a further embodiment, pharmaceutical compositions are disclosed containing one or more GnRH receptor antagonists of this invention in combination with a pharmaceutically acceptable carrier and/or diluent.

These and other aspects of the invention will be apparent upon reference to the following detailed description. To this end, various references are set forth herein

which describe in more detail certain background information, procedures, compounds and/or compositions.

#### DETAILED DESCRIPTION OF THE INVENTION

As mentioned above, the present invention is directed generally to  
 5 compounds useful as gonadotropin-releasing hormone (GnRH) receptor antagonists. The compounds of this invention have the following structure (I):



(I)

or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof,

10 wherein:

R<sub>1a</sub> and R<sub>1b</sub> are the same or different and independently hydrogen, halogen, C<sub>1-4</sub>alkyl, or alkoxy;

R<sub>2a</sub> and R<sub>2b</sub> are the same or different and independently hydrogen, halogen, trifluoromethyl, cyano or -SO<sub>2</sub>CH<sub>3</sub>;

15 R<sub>3</sub> is hydrogen or methyl;

R<sub>4</sub> is phenyl or C<sub>3-7</sub>alkyl;

R<sub>5</sub> and R<sub>6</sub> are the same or different and independently hydrogen or C<sub>1-4</sub>alkyl; or

R<sub>5</sub> and the nitrogen to which it is attached taken together with R<sub>4</sub>  
 20 and the carbon to which it is attached form 1,2,3,4-tetrahydroisoquinoline or 2,3-dihydro-1H-isoindole;

R<sub>7</sub> is -COOH or an acid isostere; and

X is  $-\text{O}-(\text{C}_{1-6}\text{alkanediyl})$  or  $-\text{O}-(\text{C}_{1-6}\text{alkanediyl})-\text{O}-(\text{C}_{1-6}\text{alkanediyl})$  wherein each  $(\text{C}_{1-6}\text{alkanediyl})$  is optionally substituted with from 1 to 3  $\text{C}_{1-4}\text{alkyl}$  groups.

As used herein, the above terms have the following meaning:

- 5       “ $\text{C}_{1-6}\text{alkyl}$ ” means a straight chain or branched, noncyclic or cyclic, saturated aliphatic hydrocarbon containing from 1 to 6 carbon atoms. Representative saturated straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, and the like; while saturated branched alkyls include isopropyl, *sec*-butyl, isobutyl, *tert*-butyl, isopentyl, and the like. Representative
- 10       saturated cyclic alkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like; while unsaturated cyclic aliphatic hydrocarbons include cyclopentenyl and cyclohexenyl, and the like. Unsaturated aliphatic hydrocarbons contain at least one double or triple bond between adjacent carbon atoms (referred to as an “alkenyl” or “alkynyl”, respectively). Representative
- 15       straight chain and branched alkenyls include ethylenyl, propylenyl, 1-butenyl, 2-butenyl, isobutylenyl, 1-pentenyl, 2-pentenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 2,3-dimethyl-2-butenyl, and the like; while representative straight chain and branched alkynyls include acetylenyl, propynyl, 1-butyne, 2-butyne, 1-pentyne, 2-pentyne, 3-methyl-1-butyne, and the like.
- 20       “ $\text{C}_{1-4}\text{alkyl}$ ” means a straight chain or branched, noncyclic or cyclic hydrocarbon containing from 1 to 4 carbon atoms. Representative straight chain alkyls include methyl, ethyl, n-propyl, n-butyl, and the like; branched alkyls include isopropyl, *sec*-butyl, isobutyl, *tert*-butyl, and the like; while cyclic alkyls include cyclopropyl and the like.
- 25       “ $\text{C}_{3-7}\text{alkyl}$ ” means a straight chain or branched, noncyclic or cyclic hydrocarbon containing from 3 to 7 carbon atoms. Representative straight chain alkyls include n-propyl, n-butyl, n-hexyl, and the like; while branched alkyls include isopropyl, *sec*-butyl, isobutyl, *tert*-butyl, isopentyl, and the like. Representative cyclic alkyls include cyclopropyl, cyclopentyl, cyclohexyl, and the like.

“C<sub>1-6</sub>alkanediyl” means a divalent C<sub>1-6</sub>alkyl from which two hydrogen atoms are taken from the same carbon atom or from different carbon atoms, such as –CH<sub>2</sub>–, –CH<sub>2</sub>CH<sub>2</sub>–, –CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>–, –CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>–, –CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>–, and the like.

“Halogen” means fluoro, chloro, bromo or iodo, typically fluoro and  
5 chloro.


“Hydroxy” means –OH.

“Alkoxy” means –O-(C<sub>1-6</sub>alkyl).

“Cyano” means –CN.


“Acid isostere” means an moiety that exhibits properties similar  
10 carboxylic acid, and which has a pK<sub>a</sub> of less than 8 and preferably less than 7. Representative acid isosteres include tetrazole, 3H-[1,3,4]oxadiazol-2-one, [1,2,4]oxadiazol-3-one, 1,2-dihydro-[1,2,4]triazol-3-one, 2H-[1,2,4]oxadiazol-5-one, triazole substituted with a sulfonyl or sulfoxide group, imidazole substituted with a sulfonyl or sulfoxide group, [1,2,4]-oxadiazolidine-3,5-dione, [1,2,4]-thiadiazolidine-  
15 3,5-dione, imidazolidine-2,4-dione, imidazolidine-2,4,5-trione, pyrrolidine-2,5-dione and pyrrolidine-2,3,5-trione. Acid isosteres also include –C(=O)NHSO<sub>2</sub>NR<sub>a</sub>R<sub>b</sub>, –C(=O)NHSO<sub>2</sub>R<sub>b</sub>, –C(=O)NHC(=O)NR<sub>a</sub>R<sub>b</sub> and –C(=O)NHC(=O)R<sub>b</sub>, where R<sub>a</sub> is hydrogen or C<sub>1-4</sub>alkyl and R<sub>b</sub> is C<sub>1-4</sub>alkyl.

In one embodiment of the invention, R<sub>4</sub> is phenyl and representative  
20 GnRH antagonists of the present invention include compounds having the following structure (II).




(II)

In another embodiment,  $R_4$  is  $C_{3-7}$ alkyl as shown in structure (III). The  $C_{3-7}$ alkyl group may be straight chain or branched alkyl such as isobutyl as shown in structure (IV) or cyclic alkyl such as cyclohexyl as shown in structure (V).



In another embodiment  $R_5$  and the nitrogen to which it is attached taken together with  $R_4$  and the carbon to which it is attached form 1,2,3,4-tetrahydroisoquinoline or 2,3-dihydro-1H-isoindole as shown in structures (VI) and (VII) respectively.

10



In another embodiment,  $R_{1a}$  and  $R_{1b}$  are hydrogen, alkoxy or halogen. The alkoxy may be methoxy or ethoxy and the halogen is typically fluoro or chloro.


15 In another embodiment,  $R_{2a}$  and  $R_{2b}$  may be hydrogen, trifluoromethyl, halogen (typically fluoro or chloro) or  $-\text{SO}_2\text{CH}_3$ .

In further embodiments,  $X$  is  $-\text{OCH}_2\text{CH}_2-$ ,  $-\text{OCH}_2\text{CH}_2\text{CH}_2-$  or  $-\text{OCH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$ .

20 The compounds of the present invention may be prepared by known organic synthesis techniques, including the methods described in more detail in the Examples. In general, the compounds of structure (I) above may be made by the

following reaction schemes, wherein all substituents are as defined above unless indicated otherwise.

### Reaction Scheme 1



5


An appropriately substituted benzonitrile may be reduced using an appropriate reagent such as borane in THF and then forms urea 1. Cyclization with a reagent such as diketene gives compound 2 which may be brominated with bromine in acetic acid, N-bromosuccinimide or other brominating agent to give compound 3.

10 Alkylation gives compound 4 and Suzuki condensation with a boronic acid or boronic acid ester gives compound 5 where Q may be alkoxy, hydroxy or a group of formula -


X-R<sub>7</sub>. Deprotection of the protected amine using a typical reagent such as trifluoroacetic acid in methylene chloride gives compound **6** which may be alkylated or condensed with an aldehyde via reductive amination conditions to give a compound of formula **7**. It is possible to alter the order of the various steps to yield the compounds of

5 the present invention.


### Reaction Scheme 2



10 In a variation of Reaction Scheme 1, compound **4** undergoes deprotection to give compound **8** which may be condensed under Suzuki conditions with an appropriate boronic acid to give compound **6**.

Reaction scheme 3

Substituted phenylacetic acid ester **9** (made from the corresponding acid or purchased) and reagent such as dimethylformamide dimethylacetal are condensed to give **10**. Cyclization with urea gives a compound of formula **11**. Alkylation using, for example, a substituted benzyl bromide gives **12** which may be alkylated with an appropriate alkyl halide, mesylate or tosylate to give **5**.

Reaction Scheme 4

Compound **13** or the appropriated protected tert-butoxycarbonyl (Boc) or carbobenzyloxy (CBZ) version of Compound **13** may be dealkylated with an appropriate acid such as HBr or BBr<sub>3</sub> to give compound **14**. Reprotection of the amine functionality may be necessary before alkylation with an alkyl halide which contains an acid, ester, or acid isostere functionality gives compound **15** directly, or may yield compound **15** following hydrolysis of the ester group if present.

The compounds of the present invention may generally be utilized as the free acid or free base. Alternatively, the compounds of this invention may be used in the form of acid or base addition salts. Acid addition salts of the free amino compounds of the present invention may be prepared by methods well known in the art, and may be formed from organic and inorganic acids. Suitable organic acids include maleic, fumaric, benzoic, ascorbic, succinic, methanesulfonic, acetic, trifluoroacetic, oxalic, propionic, tartaric, salicylic, citric, gluconic, lactic, mandelic, cinnamic, aspartic, stearic, palmitic, glycolic, glutamic, and benzenesulfonic acids. Suitable inorganic acids include hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids. Base addition salts included those salts that form with the carboxylate anion and include salts formed with organic and inorganic cations such as those chosen from the alkali and alkaline earth metals (for example, lithium, sodium, potassium, magnesium, barium and calcium), as well as the ammonium ion and substituted derivatives thereof (for example, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, and the like). Thus, the term "pharmaceutically acceptable salt" of structure (I) is intended to encompass any and all acceptable salt forms.

In addition, prodrugs are also included within the context of this invention. Prodrugs are any covalently bonded carriers that release a compound of structure (I) *in vivo* when such prodrug is administered to a patient. Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or *in vivo*, yielding the parent compound. Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or sulfhydryl groups. Thus, representative examples of

prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol and amine functional groups of the compounds of structure (I). Further, in the case of a carboxylic acid (-COOH), esters may be employed, such as methyl esters, ethyl esters, and the like.

5               With regard to stereoisomers, the compounds of structure (I) may have chiral centers and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof. Furthermore, some of the crystalline forms of the compounds of structure (I) may exist as polymorphs, which are included in the  
10 present invention. In addition, some of the compounds of structure (I) may also form solvates with water or other organic solvents. Such solvates are similarly included within the scope of this invention.

The effectiveness of a compound as a GnRH receptor antagonist may be determined by various assay techniques. Assay techniques well known in the field  
15 include the use of cultured pituitary cells for measuring GnRH activity (Vale et al., *Endocrinology* 91:562-572, 1972) and the measurement of radioligand binding to rat pituitary membranes (Perrin et al., *Mol. Pharmacol.* 23:44-51, 1983) or to membranes from cells expressing cloned receptors as described below. Other assay techniques include (but are not limited to) measurement of the effects of GnRH receptor  
20 antagonists on the inhibition of GnRH-stimulated calcium flux, modulation of phosphoinositol hydrolysis, and the circulating concentrations of gonadotropins in the castrate animal. Descriptions of these techniques, the synthesis of radiolabeled ligand, the employment of radiolabeled ligand in radioimmunoassay, and the measurement of the effectiveness of a compound as a GnRH receptor antagonist follow.

#### 25   Inhibition of GnRH stimulated LH release

Suitable GnRH antagonists are capable of inhibiting the specific binding of GnRH to its receptor and antagonizing activities associated with GnRH. For example, inhibition of GnRH stimulated LH release in immature rats may be measured according to the method of Vilchez-Martinez (*Endocrinology* 96:1130-1134, 1975).

Briefly, twenty-five day old male Sprague-Dawley rats are administered an GnRH antagonist in saline or other suitable formulation by oral gavage, subcutaneous injection, or intravenous injection. This is followed by subcutaneous injection of 200 ng GnRH in 0.2 mL saline. Thirty minutes after the last injection, the animals are  
5 decapitated and trunk blood is collected. After centrifugation, the separated plasma is stored at  $-20^{\circ}\text{C}$  until determination of the concentrations of LH and/or FSH by radioimmunoassay (see below.)

#### Rat Anterior Pituitary Cell Culture Assay of GnRH Antagonists

Anterior pituitary glands are collected from 7-week-old female Sprague-  
10 Dawley rats and the harvested glands are digested with collagenase in a dispersion flask for 1.5 hr at  $37^{\circ}\text{C}$ . After collagenase digestion, the glands are further digested with neuraminidase for 9 min at  $37^{\circ}\text{C}$ . The digested tissue is then washed with 0.1 % BSA/McCoy's 5A medium, and the washed cells are suspended in 3 % FBS/0.1 BSA/McCoy's 5A medium and plated onto 96-well tissue culture plates at a cell density  
15 of 40,000 cells per well in 200  $\mu\text{l}$  medium. The cells are then incubated at  $37^{\circ}\text{C}$  for 3 days. For assay of an GnRH antagonist, the incubated cells are first washed with 0.1 % BSA/McCoy's 5A medium once, followed by addition of the test sample plus 1nM GnRH in 200  $\mu\text{l}$  0.1 % BSA/McCoy's 5A medium in triplicate wells. Each sample is assayed at 5-dose levels to generate a dose-response curve for determination of the  
20 potency on the inhibition of GnRH stimulated LH and/or FSH release. After 4-hr incubation at  $37^{\circ}\text{C}$ , the medium is harvested and the level of LH and/or FSH secreted into the medium is determined by RIA.

#### Membrane Binding Assays 1

Cells stably, or transiently, transfected with GnRH receptor expression  
25 vectors are harvested, resuspended in 5% sucrose and homogenized using a polytron homogenizer (2x15 sec). Nucleii are removed by centrifugation (3000 x g for 5 min.), and the supernatant is centrifuged (20,000 x g for 30 min,  $4^{\circ}\text{C}$ ) to collect the membrane fraction. The final membrane preparation is resuspended in binding buffer (10mM

Hepes (pH 7.5), 150 mM NaCl, and 0.1% BSA) and stored at  $-70^{\circ}\text{C}$ . Binding reactions are performed in a Millipore MultiScreen<sup>TM</sup> 96-well filtration plate assembly with polyethylenimine coated GF/C membranes. The reaction is initiated by adding membranes (40  $\mu\text{g}$  protein in 130  $\mu\text{l}$  binding buffer) to 50  $\mu\text{l}$  of [ $^{125}\text{I}$ ]-labeled GnRH peptide (~100,000 cpm) and 20  $\mu\text{l}$  of competitor at varying concentrations. The reaction is terminated after 90 minutes by application of vacuum and washing (2X) with phosphate buffered saline. Bound radioactivity is measured using 96-well scintillation counting (Packard Topcount<sup>TM</sup>) or by removing the filters from the plate and direct gamma counting.  $K_i$  values are calculated from competition binding data using non-linear least squares regression using the Prism<sup>TM</sup> software package (GraphPad<sup>TM</sup> Software).

#### Membrane Binding Assays 2

For additional membrane binding assays, stably transfected HEK293 cells are harvested by striking tissue culture flasks against a firm surface and collected by centrifugation at 1000xg for 5 minutes. Cell pellets are resuspended in 5% sucrose and homogenized using a polytron homogenizer for two 15 second homogenization steps. Cell homogenates are then centrifuged for 5 minutes at 3000xg to remove nuclei, and the supernatant is subsequently centrifuged for 30 minutes at 44,000xg to collect the membrane fraction. The membrane pellet is resuspended in GnRH binding buffer (10 mM HEPES, pH 7.5, 150 mM NaCl and 0.1%BSA,) and aliquots are immediately snap-frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$ . Protein content of the membrane suspension is determined using the Bio-Rad<sup>TM</sup> protein assay kit (Bio-Rad, Hercules, CA).

Competitive radioligand binding assays with membrane preparations are performed in Millipore 96-well filtration plates with GF/C membrane filters which are pre-coated with 200  $\mu\text{l}$  of 0.1% polyethylenimine (Sigma, St. Louis. MO). Prior to use, the plates are washed 3X with phosphate buffered saline solution. Membrane fraction in GnRH binding buffer (130  $\mu\text{l}$  containing 25  $\mu\text{g}$  protein for human and macaque receptors or 12  $\mu\text{g}$  for rat receptors) are added to wells together with 20  $\mu\text{l}$  of competing

ligand at varying concentrations. The binding reaction is initiated by addition of radioligand (0.1nM in 50  $\mu$ l GnRH binding buffer.) The reaction is allowed to proceed for 90 min on a platform shaker at room temperature and then terminated by placing assay plate on a Millipore vacuum manifold (Millipore, Bedford, MA), aspirating the solvent, and washing wells twice with 200  $\mu$ l ice cold phosphate buffered saline (PBS). Filters in the wells are removed and counted in a gamma counter.  $K_i$  values are calculated from each competition binding curves using non-linear least square regression and corrected for radioligand concentration using the Cheng-Prusoff equation (Prism, GraphPad Software, San Diego, CA) assuming a radioligand affinity of 0.5 nM. Mean  $K_i$  values are calculated from the antilog of the mean of the  $pK_i$  values for each receptor ligand pair.

### Membrane Binding Assays 3

Stably transfected human GNRH receptor RBL cells are grown to confluence. The medium is removed and the cell monolayer is washed once with DPBS. A solution of 0.5 mM EDTA/PBS ( $Ca^{++}$   $Mg^{++}$  free) is added to the plate which is then incubated at 37 °C for 10 min. Cells are dislodged by gentle rapping of the flasks. The cells are collected and pelleted by centrifugation at 800g for 10 min at 4 °C. The cell pellet is then resuspended in buffer [DPBS (1.5 mM  $KH_2PO_4$ , 8.1mM  $Na_2HPO_4$ , 2.7 mM KCl, and 138 mM NaCl) supplemented with 10 mM  $MgCl_2$ , 2 mM EGTA, pH=7.4 with NaOH]. Cell lysis is then performed using a pressure cell and applying  $N_2$  at a pressure of 900psi for 30 min at 4 °C. Unbroken cells and larger debris are removed by centrifugation at 1200g for 10 min at 4 °C. The cell membrane supernatant is then centrifuged at 45,000g and the resulting membrane pellet is resuspended in assay buffer and homogenized on ice using a tissue homogenizer. Protein concentrations are determined using the Coomassie Plus<sup>TM</sup> Protein Reagent kit (Pierce, Rockford, IL) using bovine serum albumin as a standard. The pellets are aliquoted and stored at -80 °C until use. Titration analysis using a range of protein concentrations determined the optimal protein concentration to be 15  $\mu$ g per well final concentration.

UniFilter<sup>TM</sup> GF/C filter plates (Perkin Elmer, Boston MA ) are pretreated with a solution of 0.5% polyethyleneimine in distilled water for 30 minutes. Filters are pre-rinsed with 200 µl per well of PBS, 1% BSA (Fraction V) and 0.01% Tween-20, pH = 7.4) using a cell harvester (UniFilter-96 Filtermate; Packard). Membranes are  
 5 harvested by rapid vacuum filtration and washed 3 times with 250 µl of ice-cold buffer (PBS, 0.01% Tween-20<sup>TM</sup>, pH = 7.4). Plates are air dried, 50 µl scintillation fluid (Microscint 20<sup>TM</sup>; Packard) is added, and the plate is monitored for radioactivity using a TopCount NXT<sup>TM</sup> (Packard Instruments, IL).

Binding experiments are performed in buffer containing 10mM HEPES,  
 10 150mM NaCl, and 0.1% BSA, pH=7.5. Membranes are incubated with 50 µl [<sup>125</sup>I] His<sup>5</sup>, D-Tyr<sup>6</sup> GnRH (0.2nM final concentration) and 50 µl of small molecule competitors at concentrations ranging from 30 pM to 10 µM for a total volume in each well of 200 µl. Incubations are carried out for 2hrs at room temperature. The reaction is terminated by rapid filtration over GF/C filters as previously described. Curve fitting  
 15 is performed using Excel Fit<sup>TM</sup> Software (IDBS, Emeryville, CA). The Ki values are calculated using the method of Cheng and Prusoff (Cheng and Prusoff, 1973) using a Kd value of 0.7nM for the radioligand which was previously determined in saturation binding experiments.

#### Ca<sup>++</sup> flux measurement

20 To determine the inhibition of GnRH-stimulated calcium flux in cells expressing the human GnRH receptor, a 96-well plate is seeded with RBL cells stably transfected with the human GnRH receptor at a density of 50,000 cells/well and allowed to attach overnight. Cells are loaded for 1hr at 37 °C in the following medium: DMEM with 20 mM HEPES, 10%FBS, 2 µM Fluo-4, 0.02% pluronic acid and 2.5 mM  
 25 probenecid. Cells are washed 4 times with wash buffer (Hanks balanced salt, 20 mM HEPES, 2.5mM probenecid) after loading, leaving 150 µl in the well after the last wash. GnRH is diluted in 0.1% BSA containing FLIPR<sup>TM</sup> buffer (Hanks balanced salt, 20 mM HEPES) to a concentration of 20nM and dispensed into a 96-well plate (Low protein binding). Various concentrations of antagonists are prepared in 0.1%

BSA/FLIPR buffer in a third 96-well plate. Measurement of fluorescence due to GnRH stimulated (50  $\mu$ l of 20nM, or 4 nM final)  $\text{Ca}^{++}$  flux is performed according to manufacturer's instructions on a FLIPR<sup>TM</sup> system (Molecular Devices, FLIPR384 system, Sunnyvale, CA) following a 1-minute incubation with 50  $\mu$ l of antagonist at  
 5 varying concentrations.

#### Phosphoinositol hydrolysis assay

The procedure is modified from published protocols (W.Zhou et al; *J.Biol.Chem.* 270(32), pp18853-18857, 1995). Briefly, RBL cells stably transfected with human GnRH receptors are seeded in 24 well plates at a density of 200, 000  
 10 cell/well for 24 hrs. Cells are washed once with inositol-free medium containing 10% dialyzed FBS and then labeled with 1 $\mu$ Ci/mL of [*myo*-<sup>3</sup>H]-inositol. After 20-24 hrs, cells are washed with buffer (140 mM NaCl, 4 mM KCl, 20 mM Hepes, 8.3 mM glucose, 1 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub> and 0.1%BSA) and treated with native GnRH peptide in the same buffer with or without various concentrations of antagonist and 10  
 15 mM LiCl for 1 hour at 37 °C. Cells are extracted with 10 mM formic acid at 4 °C for 30min and loaded on a Dowex<sup>TM</sup> AG1-X8 column, washed and eluted with 1 M ammonium formate and 0.1 M formic acid. The eluate is counted in a scintillation counter. Data from PI hydrolysis assay are plotted using non-linear least square regression by the Prism<sup>TM</sup> program (Graphpad, GraphPad Software, San Diego, CA),  
 20 from which dose ratio is also calculated. The Schild linear plot is generated from the dose-ratios obtained in four independent experiments by linear regression, and the X-intercept is used to determine the affinity of the antagonist.

#### Castrate animal studies

Studies of castrate animals provide a sensitive in vivo assay for the  
 25 effects of GnRH antagonist (*Andrology* 25: 141-147, 1993). GnRH receptors in the pituitary gland mediate GnRH-stimulated LH release into the circulation. Castration results in elevated levels of circulating LH due to reduction of the negative feedback of gonadal steroids resulting in enhancement of GnRH stimulated LH release.

Consequently, measurement of suppression of circulating LH levels in castrated macaques can be used as a sensitive *in vivo* measure of GnRH antagonism. Therefore, male macaques are surgically castrated and allowed to recover for four-weeks at which point elevated levels of LH are present. Animals are then administered the test  
 5 compound as an oral or i.v. dose and serial blood samples taken for measurement of LH. LH concentrations in serum from these animals can be determined by immunoassay or bioassay techniques (*Endocrinology* 107: 902-907, 1980).

#### Preparation of GnRH Radioligand

The GnRH analog is labeled by the chloramine-T method. To 10 µg of  
 10 peptide in 20 µl of 0.5M sodium phosphate buffer, pH 7.6, is added 1 mCi of Na<sup>125</sup>I, followed by 22.5 µg chloramine-T in 15 µl 0.05M sodium phosphate buffer and the mixture is vortexed for 20 sec. The reaction is stopped by the addition of 60 µg sodium metabisulfite in 30 µl 0.05M sodium phosphate buffer and the free iodine is removed by passing the reaction mixture through a C-8 Sep-Pak<sup>TM</sup> cartridge (Millipore Corp.,  
 15 Milford, MA). The peptide is eluted with a small volume of 80% acetonitrile/water. The recovered labeled peptide is further purified by reverse phase HPLC on a Vydac<sup>TM</sup> C-18 analytical column (The Separations Group, Hesperia, CA) on a Beckman<sup>TM</sup> 334 gradient HPLC system using a gradient of acetonitrile in 0.1% TFA. The purified radioactive peptide is stored in 0.1% BSA/20% acetonitrile/0.1% TFA at -80 °C and  
 20 can be used for up to 4 weeks.

#### RIA of LH and FSH

For determination of the LH levels, each sample medium is assayed in duplicates and all dilutions are done with RIA buffer (0.01M sodium phosphate buffer/0.15M NaCl/1% BSA/0.01% NaN<sub>3</sub>, pH 7.5) and the assay kit is obtained from  
 25 the Nation Hormone and Pituitary Program supported by NIDDK. To a 12x75 mm polyethylene test tube is added 100 µl of sample medium diluted 1:5 or rLH standard in RIA buffer and 100 µl of [125I]-labeled rLH (~30,000 cpm) plus 100 µl of rabbit anti-rLH antibody diluted 1:187,500 and 100 µl RIA buffer. The mixture is incubated at

room temperature over-night. In the next day, 100 µl of goat anti-rabbit IgG diluted 1:20 and 100 µl of normal rabbit serum diluted 1:1000 are added and the mixture incubated for another 3 hr at room temperature. The incubated tubes are then centrifuged at 3,000 rpm for 30 min and the supernatant removed by suction. The remaining pellet in the tubes is counted in a gamma-counter. RIA of FSH is done in a similar fashion as the assay for LH with substitution of the LH antibody by the FSH antibody diluted 1:30,000 and the labeled rLH by the labeled rFSH.

#### Activity of GnRH receptor antagonists

Activity of GnRH receptor antagonists are typically calculated from the  $IC_{50}$  as the concentration of a compound necessary to displace 50% of the radiolabeled ligand from the GnRH receptor, and is reported as a " $K_i$ " value calculated by the following equation:

$$K_i = \frac{IC_{50}}{1 + L / K_D}$$

where L = radioligand and  $K_D$  = affinity of radioligand for receptor (Cheng and Prusoff, *Biochem. Pharmacol.* 22:3099, 1973). GnRH receptor antagonists of this invention have a  $K_i$  of 100 µM or less. In a preferred embodiment of this invention, the GnRH receptor antagonists have a  $K_i$  of less than 10 µM, and more preferably less than 1 µM, and even more preferably less than 0.1 µM (*i.e.*, 100 nM). To this end, all compounds specifically disclosed in the Examples have  $K_i$ 's of less than 100 nM in one or more of Membrane Binding Assays 1 through 3 above.

The ability of the GnRH antagonists to inhibit the major drug metabolizing enzymes in the human liver, namely, CYP2D6 and CYP3A4, can be evaluated *in vitro* according to a microtiter plate-based fluorimetric method described by Crespi et al. (*Anal. Biochem.* 248: 188-190; 1997). AMMC (*i.e.*, 3-[2-(N,N-Diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin) and BFC (*i.e.*, 7-benzyloxy-4-(trifluoromethyl)coumarin) at a concentration equal to  $K_m$  (that is, the concentration of substrate that produces one half of the maximal velocity) are used as marker substrates for CYP2D6 and CYP3A4, respectively. Briefly, recombinant CYP2D6 or

CYP3A4 is incubated with marker substrate and NADPH generating system (consisting of 1 mM NADP<sup>+</sup>, 46 mM glucose-6-phosphate and 3 units/mL glucose-6-phosphate dehydrogenase) at 37°C, in the absence or presence of 0.03, 0.09, 0.27, 0.82, 2.5, 7.4, 22, 67 and 200  $\mu$ M of a sample GnRH antagonist. Reactions are stopped by the  
5 addition of an equal volume of acetonitrile. The precipitated protein is removed by centrifugation and the clear supernatant fluid is analyzed using a microtiter plate fluorimeter. GnRH antagonists of the present invention preferably have  $K_i$ 's greater than 250 nM, more preferably greater than 1  $\mu$ M and most preferably greater than 5  $\mu$ M.

10 As mentioned above, the GnRH receptor antagonists of this invention have utility over a wide range of therapeutic applications, and may be used to treat a variety of sex-hormone related conditions in both men and women, as well as mammals in general. For example, such conditions include endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent  
15 neoplasia such as cancers of the prostate, breast and ovary, gonadotrophe pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (*e.g.*, assisted reproductive therapy such as *in vitro* fertilization).

The compounds of this invention are also useful as an adjunct to  
20 treatment of growth hormone deficiency and short stature, and for the treatment of systemic lupus erythematosus.

In addition, the compounds are useful in combination with androgens, estrogens, progesterones, and antiestrogens and antiprogestogens for the treatment of endometriosis, fibroids, and in contraception, as well as in combination with an  
25 angiotensin-converting enzyme inhibitor, an angiotensin II-receptor antagonist, or a renin inhibitor for the treatment of uterine fibroids. The compounds may also be used in combination with bisphosphonates and other agents for the treatment and/or prevention of disturbances of calcium, phosphate and bone metabolism, and in combination with estrogens, progesterones and/or androgens for the prevention or

treatment of bone loss or hypogonadal symptoms such as hot flashes during therapy with a GnRH antagonist.

In another embodiment of the invention, pharmaceutical compositions containing one or more GnRH receptor antagonists are disclosed. For the purposes of administration, the compounds of the present invention may be formulated as pharmaceutical compositions. Pharmaceutical compositions of the present invention comprise a GnRH receptor antagonist of the present invention and a pharmaceutically acceptable carrier and/or diluent. The GnRH receptor antagonist is present in the composition in an amount which is effective to treat a particular disorder--that is, in an amount sufficient to achieve GnRH receptor antagonist activity, and preferably with acceptable toxicity to the patient. Typically, the pharmaceutical compositions of the present invention may include a GnRH receptor antagonist in an amount from 0.1 mg to 250 mg per dosage depending upon the route of administration, and more typically from 1 mg to 60 mg. Appropriate concentrations and dosages can be readily determined by one skilled in the art.

Pharmaceutically acceptable carrier and/or diluents are familiar to those skilled in the art. For compositions formulated as liquid solutions, acceptable carriers and/or diluents include saline and sterile water, and may optionally include antioxidants, buffers, bacteriostats and other common additives. The compositions can also be formulated as pills, capsules, granules, or tablets which contain, in addition to a GnRH receptor antagonist, diluents, dispersing and surface active agents, binders, and lubricants. One skilled in this art may further formulate the GnRH receptor antagonist in an appropriate manner, and in accordance with accepted practices, such as those disclosed in *Remington's Pharmaceutical Sciences*, Gennaro, Ed., Mack Publishing Co., Easton, PA 1990.

In another embodiment, the present invention provides a method for treating sex-hormone related conditions as discussed above. Such methods include administering of a compound of the present invention to a warm-blooded animal in an amount sufficient to treat the condition. In this context, "treat" includes prophylactic administration. Such methods include systemic administration of a GnRH receptor

antagonist of this invention, preferably in the form of a pharmaceutical composition as discussed above. As used herein, systemic administration includes oral and parenteral methods of administration. For oral administration, suitable pharmaceutical compositions of GnRH receptor antagonists include powders, granules, pills, tablets, 5 and capsules as well as liquids, syrups, suspensions, and emulsions. These compositions may also include flavorants, preservatives, suspending, thickening and emulsifying agents, and other pharmaceutically acceptable additives. For parental administration, the compounds of the present invention can be prepared in aqueous injection solutions which may contain, in addition to the GnRH receptor antagonist, 10 buffers, antioxidants, bacteriostats, and other additives commonly employed in such solutions.

The following example is provided for purposes of illustration, not limitation. In summary, the GnRH receptor antagonists of this invention may be assayed by the general methods disclosed above, while the following Examples disclose 15 the synthesis of representative compounds of this invention.

## EXAMPLES

### HPLC Methods for analyzing the samples

Retention time,  $t_R$ , in minutes

#### 20 Method 1 -- Supercritical Fluid Chromatography Mass Spectrum (SFC-MS)

Column: 4.6 x 150 mm Deltabond Cyano<sup>TM</sup> 5 $\mu$ M from Thermo-Hypersil-Keystone.

Mobile phase: SFC grade carbon dioxide and optima grade methanol with 1mM disodium diethylmalonate modifier.

Temperature: 50 °C

25 Pressure: 120 bar

Flow Rate: 4.8 mL/min

Gradient: 5% to 55% methanol over 1.7 min and hold at 55% for 0.8 min then return to 5% in 0.1 min for total run time of 2.6 min

Method 2 (HPLC-MS)

Column: Waters<sup>TM</sup> ODS-AQ, 2.0 x 50 mm

- 5 Mobile phase: A = water with 0.05% trifluoroacetic acid; B= acetonitrile with 0.05% trifluoroacetic acid

Gradient: 95% A/ 5%B to 5%A/95%B over 13.25 min and hold 5%A/95%B over 2 min then return to 95%A/5%B over 0.25 min.

Flow Rate: 1 mL/min

- 10 UV wavelength: 220 and 254 nM

Method 3 (HPLC-MS)

Column: BHK Lab ODS-O/B, 4.6 x 50 mm, 5 µM

Mobile phase: A = water with 0.05% trifluoroacetic acid; B = acetonitrile with 0.05% trifluoroacetic acid

- 15 Gradient: 95%A/5%B for 0.5 min, then to 90% A/10%B for 0.05 min. from 90%A/10%B to 5%A/95%B over 18.94 min, then to 1%A/99%B over 0.05 min and hold 1%A/99%B over 2.16 min. then return to 95%/5%B over 0.50 min.

Flow Rate: 2.5 mL/min.

UV wavelength: 220 and 254 nM

20 Method 4 (HPLC-MS)

Column: Waters<sup>TM</sup> ODS-AQ, 2.0 x 50 mm

Mobile phase: A = water with 0.05% trifluoroacetic acid; B = acetonitrile with 0.05% trifluoroacetic acid

- 25 Gradient: 95% A/5%B to 10%A/90%B over 2.25 min and hold 10%A/90%B over 1.0 min then return to 95%A/5%B over 0.1 min.

Flow Rate: 1 mL/min

UV wavelength: 220 and 254 nM

Method 5 (HPLC)

Column: Agilent<sup>TM</sup>, Zorbax<sup>TM</sup> SB-C18, 5 $\mu$ M, 4.6x250 mm.

Mobile phase: A = water with 0.05% trifluoroacetic acid; B = acetonitrile with 0.05% trifluoroacetic acid

- 5 Gradient: 95%A/5%B to 5%A/95%B over 50 min, then 5%A/95%B to 1%A/99%B over 0.1 min, then hold 1%A/99% for 0.8 min and back to 95%A/5% over 0.2 min, hold such gradient for 4 min.

Flow Rate: 2.0 mL/min.

UV wavelength: 220 and 254 nM

10 Method 6 (HPLC-MS)

Column: Phenomenex Synergi<sup>TM</sup> 4  $\mu$  Max-RP 80A, 50.0 x2.0 mm

Mobile phase: A=water with 0.025 % of trifluoroacetic acid; B=acetonitrile with 0.025% of trifluoroacetic acid

- Gradient: 95% A/5% B 0.25min, then 95% A/5%B to 95% B/5%A over 13 min,  
15 maintaining 95% A/5%B to 95% B/5%A over 2 min, then back to 95% A/5% B in 0.25 min.


Flow Rate: 1 mL/min

UV wavelength: 220 nM and 254 nM

20

## Example 1

3-[2(R)-AMINO-2-PHENYLETHYL]-5-(2-FLUORO-3-METHOXYPHENYL)-1-[2-FLUORO-6-(TRIFLUOROMETHYL)BENZYL]-6-METHYL-PYRIMIDINE-2,4(1*H*,3*H*)-DIONE



1-1

Step 1A: Preparation of 2-fluoro-6-(trifluoromethyl)benzylamine 1a

To 2-fluoro-6-(trifluoromethyl)benzonitrile (45 g, 0.238 mmol) in 60 mL of THF was added 1 M BH<sub>3</sub>:THF slowly at 60 °C and the resulting solution was refluxed overnight. The reaction mixture was cooled to ambient temperature. 5 Methanol (420 mL) was added slowly and stirred well. The solvents were then evaporated and the residue was partitioned between EtOAc and water. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation gave **1a** as a yellow oil (46 g, 0.238 mmol). MS (CI) *m/z* 194.0 (MH<sup>+</sup>).

Step 1B: Preparation of *N*-[2-fluoro-6-(trifluoromethyl)benzyl]urea 1b

10 To 2-fluoro-6-(trifluoromethyl)benzylamine **1a** (51.5 g, 0.267 mmol) in a flask, urea (64 g, 1.07 mmol), HCl (conc., 30.9 mmol, 0.374 mmol) and water (111 mL) were added. The mixture was refluxed for 6 hours. The mixture was cooled to ambient temperature, further cooled with ice and filtered to give a yellow solid. Recrystallization with 400 mL of EtOAc gave **1b** as a white solid (46.2 g, 0.196 mmol). 15 MS (CI) *m/z* 237.0 (MH<sup>+</sup>).

Step 1C: Preparation of 1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1*H*,3*H*)-dione 1c

NaI (43.9 g, 293 mmol) was added to *N*-[2-fluoro-6-(trifluoromethyl)benzyl]urea **1b** (46.2 g, 19.6 mmol) in 365 mL of acetonitrile. The 20 resulting mixture was cooled in an ice-water bath. Diketene (22.5 mL, 293 mmol) was added slowly *via* dropping funnel followed by addition of TMSCl (37.2 mL, 293 mmol) in the same manner. The resulting yellow suspension was allowed to warm to room temperature slowly and was stirred for 20 hours. LC-MS showed the disappearance of starting material. To the yellow mixture 525 mL of water was added and stirred 25 overnight. After another 20 hours stirring, the precipitate was filtered *via* Buchner funnel and the yellow solid was washed with water and EtOAc to give **1c** as a white solid (48.5 g, 16 mmol). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.152 (s, 3H), 5.365 (s, 2H), 5.593 (s, 1H), 7.226-7.560 (m, 3H), 9.015 (s, 1H); MS (CI) *m/z* 303.0 (MH<sup>+</sup>).

Step 1D: Preparation of 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1*H*,3*H*)-dione 1d

Bromine (16.5 mL, 0.32 mmol) was added to 1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1*H*,3*H*)-dione **1c** (48.5 g, 0.16 mol) in 145 mL of acetic acid. The resulting mixture became clear then formed precipitate within an hour. After 2 hours stirring, the yellow solid was filtered and washed with cold EtOAc to an almost white solid. The filtrate was washed with sat. NaHCO<sub>3</sub> and dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation gave a yellow solid which was washed with EtOAc to give a light yellow solid. The two solids were combined to give 59.4 g of **1d** (0.156 mol) total. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.422 (s, 3H), 5.478 (s, 2H), 7.246-7.582 (m, 3H), 8.611 (s, 1H); MS (CI) *m/z* 380.9 (MH<sup>+</sup>).

5-Bromo-1-[2, 6-difluorobenzyl]-6-methylpyrimidine-2,4(1*H*,3*H*)-dione **1d.1** was made using the same procedure.

Step 1E: Preparation of 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3-[2(R)-tert-butoxycarbonylamino-2-phenylethyl]-pyrimidine-2,4(1*H*,3*H*)-dione 1e

To 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1*H*,3*H*)-dione **1d** (15 g, 39.4 mmol) in 225 mL of THF were added N-t-Boc-D-phenylglycinol (11.7 g, 49.2 mmol) and triphenylphosphine (15.5 g, 59.1 mmol), followed by addition of di-*tert*-butyl azodicarboxylate (13.6 g, 59.1 mmol). The resulting yellow solution was stirred overnight. The volatiles were evaporated and the residue was purified by silica gel with 3:7 EtOAc/Hexane to give **1e** as a white solid (23.6 g, 39.4 mmol). MS (CI) *m/z* 500.0 (MH<sup>+</sup>-Boc).

Step 1F: Preparation of 3-[2(R)-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione 1f

To 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3-[2(R)-tert-butoxycarbonylamino-2-phenylethyl]-pyrimidine-2,4(1*H*,3*H*)-dione **1e** (15 g, 25


mmol) in 30 mL/90 mL of H<sub>2</sub>O/dioxane in a pressure tube were added 2-fluoro-3-methoxyphenylboronic acid (4.25 g, 25 mmol) and sodium carbonate (15.75 g, 150 mmol). N<sub>2</sub> gas was bubbled through for 10 min. Tetrakis(triphenylphosphine)palladium (2.9 g, 2.5 mmol) was added, the tube was sealed and the resulting mixture was heated at 90 °C overnight. After cooling to ambient temperature, the precipitate was removed by filtration. The volatiles were removed by evaporation and the residue was partitioned between EtOAc/sat. NaHCO<sub>3</sub>. The organic solvent was evaporated and the residue was chromatographed with 2:3 EtOAc/Hexane to give 13.4 g (20.8 mmol, 83 %) yellow solid.

This yellow solid (6.9 g, 10.7 mmol) was dissolved in 20 mL/20 mL CH<sub>2</sub>Cl<sub>2</sub>/TFA. The resulting yellow solution was stirred at room temperature for 2 hours. The volatiles were evaporated and the residue was partitioned between EtOAc/sat. NaHCO<sub>3</sub>. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>. Evaporation gave **1f** as a yellow oil (4.3 g, 7.9 mmol, 74%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.031 (s, 3H), 3.724-4.586 (m, 6H), 5.32-5.609 (m, 2H), 6.736-7.558 (m, 11H); MS (CI) *m/z* 546.0 (MH<sup>+</sup>).

3-[2(R)-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2,6-difluorobenzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione **1f.1** was made using the same procedure described in this example.

## EXAMPLE 2

3-[2(R)-AMINO-2-CYCLOHEXYLETHYL]-5-(2-FLUORO-3-METHOXYPHENYL)-1-[2,6-DIFLUOROBENZYL]-6-METHYL-PYRIMIDINE-2,4(1*H*,3*H*)-DIONE



Step 2A: Preparation of *tert*-butyl 1-cyclohexyl-2-hydroxyethylcarbamate **2a**

A solution of N-(*t*-butoxycarbonyl)cyclohexylglycine (2.0 g, 7.77 mmol) in anhydrous THF (10 mL) was cooled to 0 °C. Borane solution (1 M in THF, 15.5 mL, 15.5 mmol) was added slowly and the reaction mixture was warmed to room temperature and stirred for 2 hours. The reaction was quenched with MeOH (5 mL), volatiles were evaporated and the residue was partitioned between water and EtOAc. The organic layer was washed with saturated NaHCO<sub>3</sub>/water, brine, dried (sodium sulfate), and evaporated to give *tert*-butyl 1-cyclohexyl-2-hydroxyethylcarbamate **2a** (1.26 g, 66.7 %), MS (CI) *m/z* 144.20 (MH<sup>+</sup>–Boc).

10 Step 2B: Preparation of 5-bromo-3-[2(R)-*tert*-butoxycarbonylamino-2-cyclohexylethyl]-1-[2, 6-difluorobenzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione **2b**

A solution of *tert*-butyl 1-cyclohexyl-2-hydroxyethylcarbamate **4a** (638 mg, 2.62 mmol) in THF (10 mL) was treated with 5-bromo-1-(2,6-difluorobenzyl)-6-methylpyrimidine-2,4(1*H*,3*H*)-dione **1d.1** (869 mg, 2.62 mmol) and triphenylphosphine (1.03g, 3.93 mmol) at ambient temperature, then di-*tert*-butylazodicarboxylate (906 mg, 3.93 mmol) was introduced. The reaction mixture was stirred at ambient temperature for 16 hours and volatiles were evaporated. The residue was partitioned between saturated NaHCO<sub>3</sub>/H<sub>2</sub>O and EtOAc. The organic layer was dried (sodium sulfate), evaporated, and purified by flash chromatography (silica, 25 % EtOAc/hexanes) to give compound **2b** (1.39 g, 95.4 %). MS (CI) *m/z* 456.10, 458.10 (MH<sup>+</sup>–Boc).

Step 2C: Preparation of 3-[2(R)-*tert*-butoxycarbonylamino-2-cyclohexylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2, 6-difluorobenzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione **2c**

5-Bromo-3-[2(R)-*tert*-butoxycarbonylamino-2-cyclohexylethyl]-1-[2, 6-difluorobenzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione **2b** (1.0 g, 1.79 mmol) in benzene/EtOH/ethylene glycol dimethyl ether (20/2/22 mL) was added 2-fluoro-3-methoxyphenylboronic acid (382 mg, 2.24 mmol) and saturated Ba(OH)<sub>2</sub>/water (~ 0.5 M, 15 mL). The reaction mixture was deoxygenated with N<sub>2</sub> for 10 minutes,


tetrakis(triphenylphosine) palladium (0) (208 mg, 0.18 mmol) was added and the reaction mixture was heated at 80 °C overnight under N<sub>2</sub>. The reaction mixture was partitioned between brine and EtOAc. The organic layer was dried (sodium sulfate), evaporated, and purified by flash chromatography (silica, 30 % EtOAc/hexanes) to give  
 5 compound **2c** (348 mg, 32.3 %). MS (CI) *m/z* 502.20 (MH<sup>+</sup>–Boc).

Step 2D: Preparation of 3-[2(R)-amino-2-cyclohexylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2, 6-difluorobenzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione **2d**

To compound **2c** (300 mg, 0.5 mmol) in dichloromethane (DCM, 2 mL) was added TFA (2 mL) and the reaction mixture was stirred at ambient temperature for  
 10 1 hour. Volatiles were evaporated and the residue was partitioned between saturated NaHCO<sub>3</sub>/water and EtOAc. The organic layer was dried (sodium sulfate), evaporated, purified by reverse phase HPLC (C-18 column, 15-75 % ACN/water) to give compound **2d**. MS (CI) *m/z* 502.20 (MH<sup>+</sup>).

### EXAMPLE 3

15 3-[2(R)-AMINO-2-PHENYLETHYL]-5-(2-CHLORO-3-METHOXYPHENYL)-1-[2-FLUORO-6-(TRIFLUOROMETHYL)BENZYL]PYRIMIDINE-2,4(1*H*,3*H*)-DIONE



Step 3A: Preparation of 2-chloro-3-methoxybenzaldehyde **3a**

To a suspension of 3-hydroxybenzaldehyde (20.12 g, 160 mmol) in  
 20 HOAc (40 mL) was added carefully tBuOCl (20 mL, 176 mmol) with stirring. The reaction became a clear solution and strongly exothermic. It was allowed to cool and

stirred for 16 hours, resulting in a white precipitate. The solid was filtered, washed with H<sub>2</sub>O and dried to give 2-chloro-3-hydroxybenzaldehyde (13.77 g, 55 %), GCMS (EI) *m/z* 156, 158 (M<sup>+</sup>).

To a solution of 2-chloro-3-hydroxybenzaldehyde (4.55 g, 29 mmol) in  
 5 DMF (30 mL) was added K<sub>2</sub>CO<sub>3</sub> (4.8 g, 34.9 mmol) followed by MeI (2.7 mL, 43.6 mmol), and the mixture was stirred at room temperature for 16 hours. Following concentration *in vacuo*, the residual was taken up in ethyl acetate, washed with H<sub>2</sub>O, brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. Purification by column chromatography on silica gel with ethyl acetate/hexanes 1/5 afforded 2-chloro-3-methoxybenzaldehyde **3a**  
 10 (4.68 g, 94 %) as a colorless oil, which solidified upon standing. GCMS (EI) *m/z* 170, 172 (M<sup>+</sup>).

Step 3B: Preparation of 2-chloro-1-methoxy-3-[2-(methylsulfanyl)-2-(methylsulfinyl)vinyl]benzene **3b**

To a solution of 2-chloro-3-methoxybenzaldehyde **3a** (4.65 g, 27.3  
 15 mmol) and methyl (methylthio)methyl sulfoxide (4.3 mL, 43.9 mmol) in THF (25 mL) was added a 40 % methanolic solution of Triton B (6.2 mL, 13.6 mmol) and the resulting solution was refluxed for 16 hours. After THF was removed, the residue was taken up in ethyl acetate, washed with 1 N HCl, H<sub>2</sub>O, and brine, then was dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. Purification by column chromatography on silica gel with  
 20 dichloromethane afforded 2-chloro-1-methoxy-3-[2-(methylsulfanyl)-2-(methylsulfinyl)vinyl]benzene **3b** (3.61 g, 48 %) as a yellow oil. GCMS (EI) *m/z* 225 (M<sup>+</sup>-Cl-16), 210 (M<sup>+</sup>-Cl-OMe).

Step 3C: Preparation of ethyl (2-chloro-3-methoxyphenyl)acetate **7c**

To a solution of 2-chloro-1-methoxy-3-[2-(methylsulfanyl)-2-(methylsulfinyl)vinyl]benzene **3b** (3.58 g, 12.9 mmol) in ethanol (20 mL) was added a  
 25 5 M ethanolic solution of HCl (5.2 mL) and the resulting solution was refluxed for 3 hours. After evaporation, the residue was purified by column chromatography on silica

gel with dichloromethane to afford ethyl (2-chloro-3-methoxyphenyl)acetate **3c** (2.78 g, 94 %) as a yellow oil. GCMS (EI)  $m/z$  228, 230 ( $M^+$ ).

Step 3D: Preparation of ethyl 2-(2-chloro-3-methoxyphenyl)-3-(dimethylamino)acrylate **3d**

5 A solution of ethyl (2-chloro-3-methoxyphenyl)acetate **3c** (2.78 g, 12 mmol) in DMFDMA (16 mL, 120 mmol) was refluxed for 16 hours. After evaporation, the residue was purified by column chromatography on silica gel with ethyl acetate/hexanes 1/2 to 1/1 to afford unreacted ethyl (2-chloro-3-methoxyphenyl)acetate **3c** (1.8 g, 65 %) first, and then ethyl 2-(2-chloro-3-methoxyphenyl)-3-  
10 (dimethylamino)acrylate **3d** (1.1 g, 32 %; 90 % based on recovered starting material) as a yellow syrup. MS (CI)  $m/z$  284.0, 286.0 ( $MH^+$ ).

Step 3E: Preparation of 5-(2-chloro-3-methoxyphenyl)pyrimidine-2,4(1H,3H)-dione **3e**

To a mixture of ethyl 2-(2-chloro-3-methoxyphenyl)-3-  
15 (dimethylamino)acrylate **3d** (1.7 g, 6 mmol), urea (1.08 g, 18 mmol) and NaI (2.7 g, 18 mmol) in acetonitrile (20 mL) was added TMSCl (2.3 mL, 18 mmol). The resulting mixture was refluxed for 16 hours, cooled to room temperature, and 1.0 M NaOH (30 mL) was added. The resultant solution was stirred for 20 hours, and acetonitrile was removed *in vacuo*. The aq. solution was washed with ether, cooled in ice bath, and  
20 neutralized with 1 N HCl (30 mL). The precipitate was filtered, washed with additional H<sub>2</sub>O, and dried to give 5-(2-chloro-3-methoxyphenyl)pyrimidine-2,4(1H,3H)-dione **3e** (1.24 g, 82 %) as a pale yellow solid. MS (CI)  $m/z$  253.1, 255.1 ( $MH^+$ ).

Step 3F: Preparation of 5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]pyrimidine-2,4(1H,3H)-dione **3f**

25 To a suspension of 5-(2-chloro-3-methoxyphenyl)pyrimidine-2,4(1H,3H)-dione **3e** (2.2 g, 8.7 mmol) in acetonitrile (25 mL) was added bis(trimethylsilyl)acetamide (4.3 mL, 17.4 mmol), and the resulting solution was

refluxed for 1.5 hours. The mixture was cooled to room temperature, 2-fluoro-3-trifluoromethylbenzyl bromide (2.7 g, 10.5 mmol) was added, and reflux was resumed for 16 hours. The reaction was quenched by addition of MeOH (25 mL) and stirring for 2 hours. After concentration, the residue was purified by column chromatography on silica gel with ethyl acetate/hexanes 1/1 to afford 5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]pyrimidine-2,4(1*H*,3*H*)-dione **3f** (3.3 g, 88 %) as a white solid. MS (CI) *m/z* 429.0, 431.0 (MH<sup>+</sup>).

Step 3G: Preparation of 3-[2(R)-(tert-butoxycarbonylamino)-2-phenylethyl]-5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]pyrimidine-2,4(1*H*,3*H*)-dione **3g**

A mixture of 5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]pyrimidine-2,4(1*H*,3*H*)-dione **3f** (75 mg, 0.175 mmol), K<sub>2</sub>CO<sub>3</sub> (72 mg, 0.525 mmol) and *N*-(*t*-butoxycarbonyl)-*D*- $\alpha$ -phenylglycinol mesylate (0.11 g, 0.35 mmol, made from *N*-(*t*-butoxycarbonyl)-*D*- $\alpha$ -phenylglycinol in THF followed by the addition of methanesulfonyl chloride and triethylamine) in DMF (2 mL) was heated at 75 °C for 16 hours. The reaction was diluted with ethyl acetate, washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by column chromatography on silica gel with ethyl acetate/hexanes 2/3 to afford compound **3g** (82 mg, 72 %) as a white solid. MS (CI) *m/z* 548.0, 550.0 (MH<sup>+</sup>-Boc).


Step 3H: Preparation of 3-[2(R)-amino-2-phenylethyl]-5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]pyrimidine-2,4(1*H*,3*H*)-dione **3h**

Compound **3g** (2.7 g, 4.2 mmol) was dissolved in dichloromethane (10 mL), TFA (14 mL, 175 mmol) was added, and the mixture was stirred at room temperature for 4.5 hours. After concentration, the residue was taken up in DCM and saturated aq. NaHCO<sub>3</sub> was added. The aq. layer was extracted with DCM. Combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give compound **3h** (2.2 g, 96 %). MS (CI) *m/z* 548.0, 550.0 (MH<sup>+</sup>).

3-[2(R)-amino-2-phenylethyl]-5-(2-chloro-3-methoxyphenyl)-1-[2, 6-difluorobenzyl]pyrimidine-2,4(1*H*,3*H*)-dione **3h.1** was prepared by substitution of the appropriate starting material using the procedures provided above.

#### EXAMPLE 4

5 3-[2(R)-AMINO-2-(ISOBUTYL)ETHYL]-5-(2-CHLORO-3-METHOXYPHENYL)-1-[2-FLUORO-6-(TRIFLUOROMETHYL)BENZYL]PYRIMIDINE-2,4(1*H*,3*H*)-DIONE



Step 4A: Preparation of 3-[2(R)-{tert-butoxycarbonyl-amino}-2-(isobutyl)ethyl]-5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]pyrimidine-

10 2,4(1*H*,3*H*)-dione **4a**

To a solution of *N*-(*t*-butoxycarbonyl)-*D*- $\alpha$ -leucinol (1.21 g, 5.57 mmol) in pyridine (6 mL) was added tosyl chloride (1.6 g, 8.35 mmol). The reaction mixture was stirred at room temperature for 3 hours, diluted with EtOAc, and washed sequentially with 1 N HCl, H<sub>2</sub>O, sat'd aq. NaHCO<sub>3</sub> and brine. The organic layer was  
15 dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated and purified by column chromatography on silica gel with ethyl acetate/hexanes 1/3 to afford [3-methyl-1-[[[(4-methylphenyl)sulfonyl]oxy]methyl]butyl]-1,1-dimethylethyl carbamic ester (1.66 g, 80 %), MS (CI) *m/z* 272.2 (MH<sup>+</sup>-Boc).

A mixture of 5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]pyrimidine-2,4(1*H*,3*H*)-dione **3f** (56 mg, 0.13 mmol), K<sub>2</sub>CO<sub>3</sub> (754 mg, 0.39 mmol) and [3-methyl-1-[[[(4-methylphenyl)sulfonyl]oxy]methyl]butyl]-1,1-dimethylethyl carbamic ester (97 mg, 0.26 mmol) in DMF (2 mL) was heated at  
20

95 °C for 16 hours. The reaction was diluted with ethyl acetate, washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by column chromatography on silica gel with ethyl acetate/hexanes 1/1 to afford recovered [3-methyl-1-[[[(4-methylphenyl)sulfonyl]oxy]methyl]butyl]-1,1-dimethylethyl carbamic ester (30 mg, 54 %) and compound **4a** (30 mg, 37 %), MS (CI) *m/z* 528.0, 530.0 (MH<sup>+</sup>-Boc).


Step 4B: Preparation of 3-[2(R)-amino-2-(isobutyl)ethyl]-5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]pyrimidine-2,4(1*H*,3*H*)-dione **4b**

To a solution of compound **4a** (30 mg, 0.048 mmol) in DCM (1 mL) was added TFA (0.1 mL, 1.3 mmol) and stirred at room temperature for 1.5 hours. After concentration, the residue was taken up in DCM and saturated aq. NaHCO<sub>3</sub> was added. The aq. layer was extracted with DCM. Combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give compound **4b**. MS (CI) *m/z* 528.0, 530.0 (MH<sup>+</sup>).

15

## EXAMPLE 5

3-[2(R)-AMINO-2-PHENYLETHYL]-5-(2-FLUORO-3-METHOXYPHENYL)-1-[2-FLUORO-6-METHYLSULFONYLBENZYL]-6-METHYL-PYRIMIDINE-2,4(1*H*,3*H*)-DIONE



Step 5A: Preparation of 3-[2(R)-tert-butoxycarbonylamino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2, 6-difluorobenzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione **5a**

To a solution of compound **1f.1** (28 g, 56 mmol) in dichloromethane (200 mL) was added a solution of di-tert-butylidicarbonate (12 g, 56 mmol) in dichloromethane (100 mL) dropwise through an addition funnel. The reaction mixture was stirred at room temperature for 2 hours and LC/MS indicated the starting material was consumed. The reaction mixture was concentrated by vacuum to yield the desired product **5a** as a light yellow solid.

Step 5B: Preparation of 3-[2(R)-tert-butoxycarbonylamino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-methylthiobenzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione **5b**

To a solution of compound **5a** (33 g, 56 mmol) in dry DMSO (100 mL) was added sodium thiomethoxide (4.0 g, 56 mmol) under nitrogen. The reaction mixture was heated to 100 °C under nitrogen for 1 hour. Another 0.28 eq. of sodium thiomethoxide (1.1 g, 16 mmol) was added, and the reaction mixture was heated to 100 °C under nitrogen for 1 hour. The reaction mixture was cooled and partitioned between ethyl ether and water. The organic layer was washed with saturated aqueous sodium bicarbonate solution and brine, dried with sodium sulfate, filtered and concentrated. The crude product was purified with a flash chromatography on silica gel eluted with 50 % ethyl acetate in hexane to yield compound **5b** as a pale yellow solid (27 g, 44 mmol, 78 %).

Step 5C: Preparation of 3-[2(R)-tert-butoxycarbonylamino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-methylsulfonylbzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione **5c**

To a solution of compound **5b** (27 g, 44 mmol) in anhydrous dichloromethane (400 mL) was added 3-chloroperoxybenzoic acid (mCPBA, 30 g, 180 mmol). The reaction mixture was stirred at room temperature overnight. The reaction


mixture was partitioned between dichloromethane and water. The organic layer was washed with saturated aqueous sodium bicarbonate solution and brine, dried with sodium sulfate, filtered and concentrated. The crude product was purified with a by chromatography on silica gel eluting with 50 % ethyl acetate in hexane to yield the  
 5 desired product compound **5c** as a pale yellow solid (15 g, 24 mmol, 53 %).

Step 5D: Preparation of 3-[2(R)-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-methylsulfonylbenzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione **5-1**

To a solution of compound **5c** (10 g, 15 mmol) in anhydrous  
 10 dichloromethane (60 mL) was added trifluoroacetic acid (TFA, 16 mL). The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated, and partitioned between ethyl acetate and diluted aqueous NaOH solution. The organic layer was washed with saturated aqueous sodium bicarbonate solution and brine, dried with sodium sulfate, filtered and concentrated to yield **5-1** as a tan solid (8.0  
 15 g, 14 mmol, 94 %).

## EXAMPLE 6

3-[2(R)-TERT-BUTOXYCARBONYLAMINO-2-PHENYLETHYL]-5-(3-HYDROXYPHENYL)-1-[2-CHLORO-6-FLUOROBENZYL]-6-METHYL-PYRIMIDINE-2,4(1H,3H)-DIONE



Step 6A: 3-[2(R)-tert-butoxycarbonylamino-2-phenylethyl]-5-bromo-1-[2-chloro-6-fluorobenzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione

N-Boc-D-phenylglycinol (2.61 g, 11.0 mmol), 5-bromo-1-[2-chloro-6-(fluoro)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione (3.48 g, 10.0 mmol), PPh<sub>3</sub> (3.95 g, 15.0 mmol) and di-*tert*-butyl azodicarboxylate (3.45 g, 15.0 mmol) in 40 mL anhydrous THF were stirred at ambient temperature under N<sub>2</sub> for 16 hours. The solvent was removed *in vacuo* and the residue was purified via silica gel (~300 g) with EtOAc/hexanes as elutant (increasing from 10% to 30% EtOAc) to give 4.29 g (76% yield) of **6a** as a foaming solid. MS (M+H)<sup>+</sup>: 466.0/468.1. NMR (CDCl<sub>3</sub>), δ, 7.41-7.25 (m, 7H), 7.03-6.97 (m, 1H), 5.60 (d, J=16.3 Hz, 1H), 5.55-5.40 (m, 1H), 5.31 (d, J = 16.3 Hz, 1H), 5.18-4.78 (m, 1H), 4.24-4.34 (m, 1H), 4.09 (dd, J = 13.2 & 3.0 Hz, 1H), 2.46 (s, 3H), 1.37 (s, 9H).


Step 6B: 3-[2(R)-tert-butoxycarbonylamino-2-phenylethyl]-5-(3-hydroxyphenyl)-1-[2-chloro-6-fluorobenzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione

Compound **6a** (4.00 g, 7.06 mmol), 3-hydroxyphenylboronic acid pinacol ester (2.33 g, 10.59 mmol), K<sub>2</sub>CO<sub>3</sub> (7.8 mL, 2N solution, 15.5 mmol), and Ba(OH)<sub>2</sub> (2.6 mL sat. solution) was suspended in 130 mL toluene and 50 mL EtOH in a tube. The mixture was purged with N<sub>2</sub> for 15 min, Pd(PPh<sub>3</sub>)<sub>4</sub> (404 mg, 0.35 mmol) was added, the tube was sealed and heated to 100 °C for 16 hours. After cooling the mixture to room temperature, the solids were filtered and the solution was evaporated. The resulting residue was purified via silica gel (30-40% EtOAc/hexanes) to give a slightly brown foaming solid **6b** (3.96 g, 98% yield). MS (M-Boc+H)<sup>+</sup>: 480.2/482.2. NMR (CDCl<sub>3</sub>), δ, 7.38-7.17 (m, 8H), 7.05-6.96 (m, 1H), 6.74 (d, J = 7.8 Hz, 1H), 6.68 (d, J = 7.8 Hz, 1H), 6.63 (s, 1H), 5.85-4.86 (m, 4H), 4.40-4.23 (m, 1H), 4.15-3.95 (m, 1H), 1.22 (s, 3H).

3-[2(R)-tert-butoxycarbonylamino-2-phenylethyl]-5-(3-hydroxyphenyl)-1-[2-fluoro-6-trifluoromethylbenzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione, compound **6b.1** was made by the same procedure.

## EXAMPLE 7

3-[2(R)-AMINO-2-PHENYLETHYL]-5-(2-FLUORO-3-([4-HYDROXYCARBONYL]-1-BUTOXY)PHENYL)-1-[2,6-DIFLUOROBENZYL]-6-METHYL-PYRIMIDINE-2,4(1*H*,3*H*)-DIONE



- 5 Step 7A: Preparation of 3-[2(R)-tert-butoxycarbonylamino-2-phenylethyl]-5-(2-fluoro-3-hydroxyphenyl)-1-[2,6-difluorobenzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione

To **1f.1** hydrochloride (2.13 g, 4 mmol) in dry dichloromethane (20 mL) at  $-78^{\circ}\text{C}$  under  $\text{N}_2$ , was added of  $\text{BBr}_3$  in dichloromethane (1M, 16 mL, 4 eq) slowly.

10 The mixture was then stirred overnight while the temperature rose gradually to room temperature. Solvent and excess of  $\text{BBr}_3$  were removed by  $\text{N}_2$  purging which resulted in a yellow solid. The solid was dissolved in MeOH to destroy possible remaining  $\text{BBr}_3$  and then concentrated again by  $\text{N}_2$  purging. The resulting solid was suspended in dichloromethane (50 mL) and TEA was added until  $\text{pH} > 8$ . Boc anhydride (698 mg,

15 0.8 eq.) was added and stirred for a few hours. TLC and HPLC-MS indicated the completion of the reaction. The mixture was concentrated and partitioned between water and ethyl acetate. The organic layer was separated, dried, and concentrated to a residue which was purified by silica gel chromatography to yield **7a** (1.5 g). MS ( $\text{M-Boc+H}^+$ ): 518.4.


Step 7B: Preparation of 3-[2(R)-tert-butoxycarbonylamino-2-phenylethyl]-5-(2-fluoro-3-([4-hydroxycarbonyl]-1-butoxy)phenyl)-1-[2,6-difluorobenzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione

To the Boc protected phenol **7a** (581 mg, 1.0 mmol) in anhydrous DMF (5 mL), added methyl 5-bromovalerate (234 mg, 1.2 mmol) and K<sub>2</sub>CO<sub>3</sub> (690 mg, 5.0 mmol). The mixture was vigorously stirred at 50 °C for 5 hours. To the stirring mixture, LiOH (240 mg, 10 mmol) was added, followed by MeOH (10 mL) and water (10 mL). The mix was heated at 80 °C for 1 hour. The mixture was cooled to room temperature, acidified with a sat. citric acid solution to pH=3, and was extracted with ethyl acetate. The organic layers were washed with water, dried and concentrated to yield an oil, which was purified by chromatography (hexane/ethyl acetate =1/1) to yield **7b** (0.68 g, foam-like). MS (M-Boc+H)<sup>+</sup>: 582.1. NMR (CDCl<sub>3</sub>), δ, 7.39-6.79 (m, 11H), 5.76 (d, J = 7.5Hz, 1H), 5.45 & 5.40 (2 m, 1H), 5.35- 4.87 9 (m, 2H), 4.41-4.28 (m, 1H), 4.10-4.5 (m, 3H), 2.46-2.42 (m, 2H), 2.13 (s, 3H), 1.88-1.80 (m, 4H), 1.38 (s, 9H).



Step 7C: Preparation of 3-[2(R)-amino-2-phenylethyl]-5-(2-fluoro-3-([4-hydroxycarbonyl]-1-butoxy)phenyl)-1-[2,6-difluorobenzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione

Compound **7b** (0.68 g) was treated in 4N HCl in dioxane (5 mL) for 2 hours. The reaction mixture was concentrated and purified by prep HPLC. The desired compound **7-1** was initially obtained as TFA salt then was desalted on HPLC to yield free amino acid product. The sodium salt was made by suspending the **7-1** free base in 50 mL of water, then gradually adding 0.2 NaOH until all material was dissolved. pH of the solution was about 9. The solution was lyophilized to give compound **7-1** sodium salt (395 mg). MS (M+1)<sup>+</sup>: 582.3. NMR (DMSO-d<sub>6</sub>), δ: 7.47-7.37 (m, 1H), 7.27-7.03 (2 m, 9H), 6.75-6.71 (m, 0.5H), 6.61-6.57 (m, 0.5H), 5.22-5.20 (m, 2H), 4.15-4.04 (m, 1H), 4.06 (t, J = 5.7Hz, 2H), 3.96-3.82 (m, 2H), 2.30 (t, J = 7.5Hz, 2H), 2.13 (s, 3H), 1.78-1.63 (m, 4H).

The following compounds were made according the above procedure:









| No. | R <sub>2a</sub>    | R <sub>4</sub> | -(C <sub>1-6</sub> alkanediyl)-R <sub>7</sub> | Mass  | MW    | t <sub>R</sub><br>(method) |
|-----|--------------------|----------------|-----------------------------------------------|-------|-------|----------------------------|
| 7-1 | F                  | Ph             |                                               | 582.1 | 581.6 | 1.037 (1)                  |
| 7-2 | Cl                 | Ph             |                                               | 598.2 | 598.0 | 8.570 (3)                  |
| 7-3 | CF <sub>3</sub>    | Ph             |                                               | 631.2 | 631.6 | 6.036 (2)                  |
| 7-4 | CF <sub>3</sub>    | cyclopentyl    |                                               | 624.2 | 623.6 | 6.390 (2)                  |
| 7-5 | SO <sub>2</sub> Me | Ph             |                                               | 628.3 | 627.7 | 5.139 (2)                  |
| 7-6 | SO <sub>2</sub> Me | Ph             |                                               | 642.1 | 641.7 | 5.361 (2)                  |
| 7-7 | CF <sub>3</sub>    | Ph             |                                               | 646.3 | 645.6 | 6.320 (2)                  |
| 7-8 | SO <sub>2</sub> Me | Ph             |                                               | 656.3 | 655.7 | 5.655 (2)                  |
| 7-9 | CF <sub>3</sub>    | isobutyl       |                                               | 626.2 | 625.6 | 1.157 (1)                  |


| No.  | R <sub>2a</sub> | R <sub>4</sub> | -(C <sub>1-6</sub> alkanediyl)-R <sub>7</sub>                                      | Mass  | MW    | t <sub>R</sub><br>(method) |
|------|-----------------|----------------|------------------------------------------------------------------------------------|-------|-------|----------------------------|
| 7-10 | CF <sub>3</sub> | isobutyl       |  | 612.2 | 611.6 | 1.160 (1)                  |
| 7-11 | F               | Ph             |  | 596.3 | 595.6 | 5.900 (2)                  |

Starting with hydroxy substituted compounds such as compounds **6b** and **6b.1** and following the procedure of Steps 7B and 7C, the following compounds were also made:

5




| No.  | R <sub>2a</sub> | -(C <sub>1-6</sub> alkanediyl)-R <sub>7</sub>                                        | Mass  | MW     | t <sub>R</sub><br>(method) |
|------|-----------------|--------------------------------------------------------------------------------------|-------|--------|----------------------------|
| 7-12 | Cl              |  | 566.1 | 566.0  | 6.990 (2)                  |
| 7-13 | Cl              |  | 580.1 | 580.0  | 1.300 (1)                  |
| 7-14 | Cl              |  | 594.4 | 594.1  | 6.108 (2)                  |
| 7-15 | CF <sub>3</sub> |  | 628.0 | 627.6  | 1.341 (1)                  |
| 7-16 | Cl              |  | 608.2 | 608.11 | 1.527 (1)                  |

| No.  | R <sub>2a</sub> | -(C <sub>1-6</sub> alkanediyl)-R <sub>7</sub>                                      | Mass  | MW    | t <sub>R</sub><br>(method) |
|------|-----------------|------------------------------------------------------------------------------------|-------|-------|----------------------------|
| 7-17 | CF <sub>3</sub> |  | 614.2 | 613.6 | 4.963 (2)                  |

## EXAMPLE 8

3-[2(R)-METHYLAMINO-2-PHENYLETHYL]-5-(2-FLUORO-3-([4-HYDROXYCARBONYL]-1-BUTOXY)PHENYL)-1-[2-FLUORO-6-(TRIFLUOROMETHYL)BENZYL]-6-METHYL-PYRIMIDINE-2,4(1*H*,3*H*)-DIONE



5

Step 8A: N-Boc-N-methyl-D-phenylglycinol

LAH (1.62 g, 5.0 eq ) was added to a round flask under nitrogen followed by the slow addition of anhydrous THF (200 mL). N-Boc-D-phenylglycinol (10 g, 42.7 mmol) was added and the reaction mixture was refluxed overnight under N<sub>2</sub>.  
 10 The mixture was cooled to room temperature, then to 0 °C and NaOH (10% solution) was added until it generated no bubbles. Another 200 mL of THF was added during the neutralization, then 50 g of NaSO<sub>4</sub> was added. After stirring, the mix was filtered and the solid was washed with THF. The combined solution was concentrated to yield 6.2 g of colorless oil. To the oil, di-tert-butyl dicarbonate (Boc<sub>2</sub>O, 13.8 g, 5 mmol) was  
 15 added. Bubbles formed right away and the mixture was diluted with toluene (10 mL)

and heated at 100 °C for 0.5 hr. A short column chromatography was used to wash out Boc<sub>2</sub>O first by hexane/ethyl acetate (8/2), then hexane/ ethyl acetate (2/8) to give compound **8a** (9.0 g, yield=85% ). MS (M-Boc+H)<sup>+</sup>: 152.2. NMR (CDCl<sub>3</sub>), δ, 7.38-7.22 (m, 5H), 5.25-5.15 (m, 1H), 4.05-4.00 (m, 2H), 2.70 (s, 3H), 1.66 (br, 1H), 1.48 (s, 9H).

Step 8B: 3-[2(R)-{N-tert-butoxycarbonyl-N-methylamino}-2-phenylethyl]-5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione

To Boc-N-methyl-D-phenylglycinol **8a** (8.9 g, 35 mmol) and 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione **1d** (12 g, 31.5 mmol) in dry THF, was added triphenylphosphine (12 g, 45.6 mmol), then di-tert butyl diazocarbonylate (10.5 g, 45.6 mmol). The mixture was stirred at room temperature overnight. The mix was concentrated and purified by column chromatography to yield 21 g of white foam **8b**. NMR indicated it contained 50% of a byproduct (*t*-BuO<sub>2</sub>CNHNHCO<sub>2</sub>-*t*Bu). MS (M-Boc+H)<sup>+</sup>: 512.2, 514.2. NMR (CDCl<sub>3</sub>), δ, 7.55 (d, J = 7.8Hz, 1H), 7.45-7.20 (m, 7H), 5.90-5.18 (m, 3H), 4.95-4.80 (m, 1H), 4.28 (dd, J = 17.1 & 5.4 Hz, 1H), 2.56 (s, 1.5H), 2.50 (s, 3H), 2.41 (s, 1.5H), 1.42 (s, 9H).

Step 8C: 3-[2(R)-{N-tert-butoxycarbonyl-N-methylamino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione

To the bromide **8b** (2.7 g, 4.4 mmol) in a mixture of 30 mL of dioxane and 6 mL of water, was added 2-fluoro-3-methoxyphenyl boronic acid (1.48 g, 2.0 eq) and Na<sub>2</sub>CO<sub>3</sub> (3.3 g, 7 eq.). The mixture was purged by N<sub>2</sub> gas for 15 min., then Pd(PPh<sub>3</sub>)<sub>4</sub> (500 mg) was added. It was then stirred at 100 °C for 12 hours with vigorous stirring and was concentrated to remove dioxane. The mixture was partitioned in ethyl acetate and water. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, then purified by column chromatography to yield 885 mg of **8c** (33%). MS(M-Boc+H)<sup>+</sup>: 560.3

Step 8D: 3-[2(R)-{N-tert-butoxycarbonyl-N-methylamino}-2-phenylethyl]-5-(2-fluoro-3-hydroxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione

Compound **8c** (885 mg, 1.34 mmole) was dissolved in dichloromethane (50 mL), cooled to  $-78^{\circ}\text{C}$  under  $\text{N}_2$ , and  $\text{BBr}_3$  (1M in dichloromethane, 5.2 mL, 4.0 eq) was added slowly. The mixture was slowly warmed to room temperature with stirring overnight. The mixture was concentrated by  $\text{N}_2$  flow, treated with MeOH (10 mL), and concentrated again to remove HBr. THF (50 mL) was added and triethylamine was added until the mix was basic.  $\text{Boc}_2\text{O}$  (2.33 g, 0.8 eq) was added and the mixture was stirred until no free amine was seen on both TLC and HPLC. The mixture was filtered, concentrated and was partitioned in EtOAc/ $\text{H}_2\text{O}$ . The organic layer was separated and concentrated to give an oil, which was purified by column chromatography to give 464 mg of **8d** (53% yield). MS (M-Boc+H)<sup>+</sup>: 546.3. NMR ( $\text{CDCl}_3$ ),  $\delta$ , 7.55 (1H, d, J = 7.8Hz, 1H), 7.46-7.38 (m, 1H), 7.37-7.22 (m, 6H), 7.17-6.92 (m, 2H), 6.76-6.68 (m, 1H), 6.08-5.36 (m, 3H), 5.36-5.18 (m, 1H), 4.87-4.83 (m, 1H), 3.31-4.20 (m, 1H), 2.70 (s, 3H), 2.16-2.10 (m, 3H), 1.42 (s, 9H).

Step 8E: 3-[2(R)-{N-tert-butoxycarbonyl-N-methylamino}-2-phenylethyl]-5-(2-fluoro-3-([4-hydroxycarbonyl]-1-butoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione


Compound **8d** (400 mg, 0.6 2mmol) was dissolved in DMF (5 mL, anhydrous), then methyl 5-bromovalerate was added (107 microliter, 1.2 eq), followed by powder  $\text{K}_2\text{CO}_3$  (430 mg, 5.0 eq). The mixture was heated at  $50^{\circ}\text{C}$  for 3 hours. MeOH (10 mL) and water (10 mL) were added, followed by addition of LiOH (148 mg, 10 eq). The mixture was heated to  $80^{\circ}\text{C}$  for a few hours. The mixture was cooled to r.t, acidified to pH=3 with aqueous  $\text{NaHSO}_4$ . The crude was partitioned in ethyl acetate/ $\text{H}_2\text{O}$ . The organic layer was separated, dried, purified by column chromatography (hexane/ethyl acetate 4/6) to yield **7e** (300mg, 65%). MS (M-Boc+H)<sup>+</sup>: 646 3.

Step 8F: 3-[2(R)-Methylamino-2-phenylethyl]-5-(2-fluoro-3-([4-hydroxycarbonyl]-1-butoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1H,3H)-dione

Compound **8e** was dissolved in 1.5 mL of dichloromethane and 1.5 mL of TFA was added. The mixture was stirred at room temperature for 1 hour, concentrated to remove TFA, partitioned in EtOAc/H<sub>2</sub>O, and sat NaHCO<sub>3</sub> was added to make the aqueous solution neutral. The organic layer was separated, concentrated, and purified by chromatography (dichloromethane/MeOH 90/10 as elutant). The resulting compound **8-1** was suspended in water (20 mL) and 0.1 N NaOH was added gradually to pH=9 and sonicated constantly until all material dissolved. The solution was lyophilized to yield 120 mg of **8-1** as the sodium salt. MS (M+H)<sup>+</sup>: 646.4. NMR (CDCl<sub>3</sub>),  $\delta$ , 7.40 (d, J=7.5 Hz, 1H), 7.37-7.14 (m, 8H), 6.98-6.81 (m, 2H), 6.69 (t, J = 7.5 Hz, 0.5H), 6.58 (t, J = 6.0Hz, 0.5H), 5.38 (s, 2H), 4.32-4.20 (m, 1H), 4.10-3.81 (m, 2H), 3.81-3.75 (m, 2H), 2.65-2.35 (br, 2H), 2.18-2.04 (m, 3H), 1.95 (s, 3H), 1.78-1.50 (m, 4H).  $t_R$  = 1.330 (Method 1)

## EXAMPLE 9

3-[(1-R-1,2,3,4-TETRAHYDROISOQUINOLINE)METHYL]-5-(3-([5-HYDROXYCARBONYL]-1-PENTOXY)PHENYL)-1-[2-FLUORO-6-(TRIFLUOROMETHYL)BENZYL]-6-METHYL-PYRIMIDINE-2,4(1H,3H)-DIONE



Step 9A: Preparation of 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3-[N-(benzyloxycarbonyl)-1(R)-1,2,3,4-tetrahydroisoquinoline)methyl]-pyrimidine-2,4(1H,3H)-dione 9a

A solution of 5-bromo-1-(2-fluoro-6-trifluoromethylbenzyl)-6-methyluracil **1d** (2.29 g, 6.0 mmol) in THF (20 mL) was treated with *N*-(benzyloxycarbonyl)-R-1-hydroxymethyl-1,2,3,4-tetrahydro-isoquinoline (1.96 g, 6.6 mmol, prepared from (R)-1,2,3,4-tetrahydro-1-isoquinoline carboxylic acid via the borane reduction of Step 2A) and triphenylphosphine (2.36 g, 9.0 mmol) at room temperature, then di-*tert*-butylazodicarboxylate (2.07 g, 9.0 mmol) was introduced in several portions over 5 min. The mixture was stirred at room temperature for 16 hr, concentrated and purified by column chromatography on silica gel eluting with ethyl acetate/hexanes 2/3 to afford compound **9a** (3.96 g, 100%), MS (CI) *m/z* 660.2, 662.2 (MH<sup>+</sup>).

Step 9B: Preparation of 5-(3-hydroxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3-[N-(benzyloxycarbonyl)-1(R)-1,2,3,4-tetrahydroisoquinoline)methyl]-pyrimidine-2,4(1H,3H)-dione 9b

To compound **9a** (3.3 g, 5.0 mmol) in dioxane/water (90/10 mL) was added 3-hydroxyphenylboronic acid (1.38 g, 10 mmol) and Na<sub>2</sub>CO<sub>3</sub> (3.18 g, 30 mmol). The mixture was deoxygenated with nitrogen for 15 min, tetrakis(triphenylphosphine) palladium (0) (0.58 g, 0.5 mmol) was added and the reaction mixture was heated at 90 °C for 16 hr. The reaction mixture was evaporated and partitioned between EtOAc and H<sub>2</sub>O. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated and purified by column chromatography on silica gel with ethyl acetate/hexanes 2/3 to 1/1 to afford compound **9b** (3.12 g, 93%). MS (CI) *m/z* 674.0 (MH<sup>+</sup>).


Step 9C: Preparation of 3-[N-(benzyloxycarbonyl)- (1-R-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(3-([5-hydroxycarbonyl]-1-pentoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione 9c

To compound **9b** (168 mg, 0.25 mmol) in DMF (1 mL) was added ethyl 6-bromohexanoate (0.053 mL, 0.3 mmol) and K<sub>2</sub>CO<sub>3</sub> (172 mg, 1.25 mmol). The mixture was heated at 80 °C and stirred vigorously for 5 hr. NaOH (0.1 g, 2.5 mmol) and MeOH/H<sub>2</sub>O (1:1, 4 mL) were then added, and heated at 80 °C for 1 hr. The reaction mixture was evaporated and partitioned between EtOAc and 1N HCl (to make aq. phase pH 3). The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated and purified by column chromatography on silica gel with ethyl acetate/hexanes 2/1 to afford compound **9c** (0.14 g, 70%). MS (CI) *m/z* 788.3 (MH<sup>+</sup>).




Step 9D: Preparation of 3-[(1-R-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(3-([5-hydroxycarbonyl]-1-pentoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione 9-1

Compound **9c** (0.14 g, 0.18 mmol) was dissolved in 80% AcOH (10 mL) and hydrogenated under 1 atm H<sub>2</sub> at room temperature for 12 hr in the presence of Pd/C (14 mg). The mixture was filtered over Celite<sup>TM</sup>, evaporated, and partitioned between EtOAc and saturated aqueous NaHCO<sub>3</sub> (to make aq. phase pH 6-7). The organic layer was washed with H<sub>2</sub>O and brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to afford compound **4** (0.114 g, 98%). MS (CI) *m/z* 654.4 (MH<sup>+</sup>).

The following compounds were made according to the above procedure:




| No. | -(C <sub>1-6</sub> alkanediyl)-R <sub>7</sub> | Mass | MW | t <sub>R</sub><br>(method) |
|-----|-----------------------------------------------|------|----|----------------------------|
|-----|-----------------------------------------------|------|----|----------------------------|

|     |                                                                                    |       |        |           |
|-----|------------------------------------------------------------------------------------|-------|--------|-----------|
| 9-1 |  | 654.0 | 653.67 | 6.827 (6) |
| 9-2 |  | 640.0 | 639.64 | 5.497 (6) |
| 9-3 |  | 626.3 | 625.62 | 4.962 (6) |

## EXAMPLE 10


3-[(N-METHYL-1-R-1,2,3,4-TETRAHYDROISOQUINOLINE)METHYL]-5-(3-([5-  
HYDROXYCARBONYL]-1-PENTOXY)PHENYL)-1-[2-FLUORO-6-  
5 (TRIFLUOROMETHYL)BENZYL]-6-METHYL-PYRIMIDINE-2,4(1*H*,3*H*)-DIONE



Step 10A: Preparation of 3-[(N-methyl-1-R-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(3-([5-hydroxycarbonyl]-1-pentoxyl)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione 10-1

10 A solution of compound **9-1** (10 mg, 0.015 mmol) and formaldehyde (7.5 M solution in water; 4  $\mu$ L, 0.03 mmol) in THF was stirred at RT for 5 min. Borane pyridine complex (8 M; 7.5  $\mu$ L) was added and stirred for 1 hr. After concentration, the residue was purified by prep LCMS to give compound **10-1**. MS (CI) *m/z* 668.4 (MH<sup>+</sup>).


The following compounds were made according to the above procedure:



| No.  | -(C <sub>1-6</sub> alkanediyl)-R <sub>7</sub> | R <sub>6</sub>                  | Mass  | MW     | t <sub>R</sub><br>(method) |
|------|-----------------------------------------------|---------------------------------|-------|--------|----------------------------|
| 10-1 |                                               | CH <sub>3</sub>                 | 668.4 | 667.70 | 6.710 (6)                  |
| 10-2 |                                               | CH <sub>3</sub>                 | 654.4 | 653.67 | 5.469 (6)                  |
| 10-3 |                                               | CH <sub>2</sub> CH <sub>3</sub> | 668.4 | 667.70 | 5.223 (6)                  |
| 10-4 |                                               | CH <sub>3</sub>                 | 640.4 | 639.64 | 4.958 (6)                  |

## EXAMPLE 11

3-[(1-R-1,2,3,4-TETRAHYDROISOQUINOLINE)METHYL]-5-(2-FLUORO-3-([4-  
 5 HYDROXYCARBONYL]-1-BUTOXY)PHENYL)-1-[2-FLUORO-6-  
 (TRIFLUOROMETHYL)BENZYL]-6-METHYL-PYRIMIDINE-2,4(1*H*,3*H*)-DIONE



Step 11A: Preparation of 5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3-[N-(benzyloxycarbonyl)-1(R)-1,2,3,4-tetrahydroisoquinoline)methyl]-pyrimidine-2,4(1H,3H)-dione 11a

To compound **9a** (0.66 g, 1.0 mmol) in dioxane/water (18/2 mL) was  
5 added 2-fluoro-3-methoxyphenylboronic acid (0.34 g, 2.0 mmol) and Na<sub>2</sub>CO<sub>3</sub> (0.64 g, 6.0 mmol). The mixture was deoxygenated with nitrogen for 15 min, tetrakis(triphenylphosphine) palladium (0) (0.12 g, 0.1 mmol) was added and the reaction mixture was heated at 90 °C for 16 hr. The reaction mixture was evaporated and partitioned between EtOAc and H<sub>2</sub>O. The organic layer was washed with brine,  
10 dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated and purified by column chromatography on silica gel with ethyl acetate/hexanes 2/3 to 1/1 to afford compound **11a** (0.57 g, 81%). MS (CI) *m/z* 705.9 (MH<sup>+</sup>).

Step 11B: Preparation of 5-(2-fluoro-3-hydroxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3-[1(R)-1,2,3,4-tetrahydroisoquinoline)methyl]-pyrimidine-2,4(1H,3H)-dione 11b

To compound **11a** (1.51 g, 2.14 mmol) in dry dichloromethane (15 mL) at -78 °C was added BBr<sub>3</sub> (1M in dichloromethane, 10.7 mL, 10.7 mmol). The mixture was stirred for 16 hr while the temperature gradually rose to room temperature. The reaction mixture was evaporated by purging with nitrogen. MeOH was added and  
20 evaporated again with nitrogen. The residue was taken up in dichloromethane (5 mL) and hexane (100 mL) was added. The resultant yellow solid was filtered, washed with hexane and dried to give crude compound **11b**. MS (CI) *m/z* 558.0 (MH<sup>+</sup>).

Step 11C: Preparation of 5-(2-fluoro-3-hydroxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-3-[N-(tert-butyloxycarbonyl)-1(R)-1,2,3,4-tetrahydroisoquinoline)methyl]-pyrimidine-2,4(1H,3H)-dione 11c

To compound **11b** in dichloromethane (15 mL) was added Et<sub>3</sub>N (about 1.2 mL) until pH > 8, followed by Boc<sub>2</sub>O (0.37 g, 1.7 mmol). The mixture was stirred for 12 hr, evaporated and partitioned between EtOAc and H<sub>2</sub>O. The organic layer was

washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated and purified by column chromatography on silica gel with ethyl acetate/hexanes 2/3 to 1/1 to afford compound **11c** (1.2 g, 85%). MS (CI) *m/z* 558.0 (MH<sup>+</sup>-Boc).


Step 11D: Preparation of 3-[N-(tert-butyloxycarbonyl)-1(R)-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-fluoro-3-([4-hydroxycarbonyl]-1-butoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione **11-1**

To compound **11c** (0.17 g, 0.26 mmol) in DMF (1 mL) was added methyl 5-bromovalerate (0.044 mL, 0.31 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.18, 1.3 mmol). The mixture was heated at 80 °C and stirred vigorously for 5 hr. NaOH (0.1 g, 2.6 mmol) and MeOH/H<sub>2</sub>O (1:1, 4 mL) were then added, and heated at 80 °C for 1 hr. The reaction mixture was evaporated and partitioned between EtOAc and 1N HCl (to make aq. phase pH 3). The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated and purified by column chromatography on silica gel with ethyl acetate/hexanes 3/1 to afford compound **11d** (0.15 g, 77%). MS (CI) *m/z* 658.0 (MH<sup>+</sup>-Boc)

Step 11E: Preparation of 3-[(1-R-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-fluoro-3-([4-hydroxycarbonyl]-1-butoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione

To a solution of compound **11d** (0.15 g, 0.2 mmol) in DCM (2 mL) was added TFA (0.4 mL, 5.2 mmol) and the mixture was stirred at RT for 1.5 hr. After concentration, the residue was taken up in EtOAc and saturated aqueous NaHCO<sub>3</sub> was added. The organic layer was separated, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give compound **11-1** (0.11 g, 84%). MS (CI) *m/z* 658.0 (MH<sup>+</sup>).


The following compounds were made according to the above procedure:



| No.  | -(C <sub>1-6</sub> alkanediyl)-<br>R <sub>7</sub> | Mass  | MW     | t <sub>R</sub><br>(method) |
|------|---------------------------------------------------|-------|--------|----------------------------|
| 11-1 |                                                   | 657.9 | 657.63 | 5.490 (6)                  |
| 11-2 |                                                   | 644.2 | 643.61 | 5.923 (6)                  |

### EXAMPLE 12

- 5 3-[(N-METHYL-1-R-1,2,3,4-TETRAHYDROISOQUINOLINE)METHYL]-5-(2-FLUORO-3-([4-HYDROXYCARBONYL]-1-BUTOXY)PHENYL)-1-[2-FLUORO-6-(TRIFLUOROMETHYL)BENZYL]-6-METHYL-PYRIMIDINE-2,4(1*H*,3*H*)-DIONE




Step 12A: Preparation of 3-[(N-Methyl-1-R-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-fluoro-3-([4-hydroxycarbonyl]-1-butoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione 12-1

A solution of compound **11-1** (15 mg, 0.023 mmol) and formaldehyde (7.5 M solution in water; 6  $\mu$ L, 0.045 mmol) in THF was stirred at room temperature for 5 min. Borane pyridine complex (8 M; 12  $\mu$ L) was added and stirred for 1 hr. After concentration, the residue was purified by prep LCMS to give compound **12-1**. MS (CI)  $m/z$  672.0 ( $MH^+$ )

The following compounds were made according to the above procedure:


10



| No.  | -(C <sub>1-6</sub> alkanediyl)-<br>R <sub>7</sub> | R <sub>6</sub>                  | Mass  | MW     | t <sub>R</sub><br>(method) |
|------|---------------------------------------------------|---------------------------------|-------|--------|----------------------------|
| 12-1 |                                                   | CH <sub>3</sub>                 | 672.0 | 671.66 | 5.672 (6)                  |
| 12-2 |                                                   | CH <sub>3</sub>                 | 658.2 | 657.63 | 5.924 (6)                  |
| 12-3 |                                                   | CH <sub>2</sub> CH <sub>3</sub> | 686.0 | 685.69 | 5.207 (6)                  |

## EXAMPLE 13

3-[(1-R-1,2,3,4-TETRAHYDROISOQUINOLINE)METHYL]-5-(2-CHLORO-3-([4-HYDROXYCARBONYL]-1-BUTOXY)PHENYL)-1-[2-FLUORO-6-(TRIFLUOROMETHYL)BENZYL]-PYRIMIDINE-2,4(1*H*,3*H*)-DIONE



5

Step 13A: Preparation of N-Benzyloxycarbonyl-1-hydroxymethyl-D-1,2,3,4-tetrahydro-isoquinoline 13a

To N-Benzyloxycarbonyl-D-1,2,3,4-tetrahydro-isoquinoline-1-carboxylic acid (3.11 g, 10 mmol, made from commercially available D-1,2,3,4-tetrahydro-isoquinoline-1-carboxylic acid and O-benzyloxycarbonyl-N-hydroxysuccinamide) in THF (10 mL) was added BH<sub>3</sub> (1M solution in THF; 30 mL, 30 mmol) over 5 min, and the reaction mixture was stirred for 3 hours. Acetic acid (9 mL) in MeOH (90 mL) was added and the mixture was stirred for 30 min. Solvents were evaporated, the residue was taken up in EtOAc and was washed with saturated aqueous NaHCO<sub>3</sub> (90 mL, aq. phase pH 7-8) and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give compound **13a** (2.97 g, 100%). MS (CI) *m/z* 253.9 (MH<sup>+</sup>-CO<sub>2</sub>), 297.9 (MH<sup>+</sup>); *t<sub>R</sub>* = 2.695 min (method 4).

Step 13B: Preparation of N-Benzyloxycarbonyl-1-(methanesulfonyloxymethyl)-D-1,2,3,4-tetrahydro-isoquinoline 13b

To a solution of compound **13a** (6.15 g, 20.7 mmol) in dichloromethane (69 mL) was added Et<sub>3</sub>N (3.17 mL, 22.8 mmol) followed by methanesulfonyl chloride


(1.76 mL, 22.8 mmol). The reaction was stirred at room temperature overnight, evaporated and partitioned between EtOAc and H<sub>2</sub>O. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give compound **13b** (7.8 g, 100%). MS (CI) *m/z* 376.0 (MH<sup>+</sup>); *t<sub>R</sub>* = 2.666 min (method 4).




5 Step 13C: Preparation of 3-[(1-R-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-pyrimidine-2,4(1*H*,3*H*)-dione **13c**

Following the procedure of Step 3G, N-Benzyloxycarbonyl-1-(methanesulfonyloxymethyl)-D-1,2,3,4-tetrahydro-isoquinoline **13b** (6.57 g, 17.52  
10 mmol) and 5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]pyrimidine-2,4(1*H*,3*H*)-dione **3f** (5.14 g, 12 mmol) formed 3-[(1-R-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-pyrimidine-2,4(1*H*,3*H*)-dione **13c** (5.73 g, 68%). MS (CI) *m/z* 708.0, 710.0 (MH<sup>+</sup>).

15 Step 13D: Preparation of 3-[(1-R-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-chloro-3-([4-hydroxycarbonyl]-1-butoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-pyrimidine-2,4(1*H*,3*H*)-dione **13-1**


Following the procedure as outlined in Steps 7A to 7C and using 3-[(1-R-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-chloro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-pyrimidine-2,4(1*H*,3*H*)-dione **13c** as starting material, the  
20 following compounds were synthesized.



| No.  | -(C <sub>1-6</sub> alkanediyl)-R <sub>7</sub>                                      | Mass  | MW     | t <sub>R</sub><br>(method) |
|------|------------------------------------------------------------------------------------|-------|--------|----------------------------|
| 13-1 |  | 660.4 | 660.06 | 5.376 (6)                  |
| 13-2 |  | 646.1 | 646.03 | 22.43 (5)                  |
| 13-3 |  | 674.1 | 674.09 | 22.52 (5)                  |

## EXAMPLE 14

3-[(1-R-1,2,3,4-TETRAHYDROISOQUINOLINE)METHYL]-5-(2-FLUORO-3-  
 ([HYDROXYCARBONYL]METHOXY-1-PROPOXY)PHENYL)-1-[2-FLUORO-6-  
 (TRIFLUOROMETHYL)BENZYL]-6-METHYL-PYRIMIDINE-2,4(1*H*,3*H*)-DIONE



5

Step 14A: Preparation of 3-[(1-R-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-fluoro-3-([3-hydroxy-1-propoxy]phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione 14a

To compound **11c** (170 mg, 0.26 mmol) in DMF (1 mL) was added  
 10 bromopropanol (43 mg, 0.31 mmol) and K<sub>2</sub>CO<sub>3</sub> (180 mg, 1.30 mmol). The mixture  
 was heated at 80 °C overnight. The reaction mixture was evaporated and partitioned  
 between EtOAc and H<sub>2</sub>O. The organic layer was washed with brine, dried over

Na<sub>2</sub>SO<sub>4</sub>, concentrated and purified on prep TLC plate with ethyl acetate/hexanes 3/2 to afford compound **14a** (0.13 g, 70%). MS (CI) *m/z* 616.0 (MH<sup>+</sup>-Boc).


Step 14B: Preparation of 3-[(1-R-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-fluoro-3-([tert-butyloxycarbonyl]methoxy-1-propoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione **14b**

To compound **14a** (130 mg, 0.18 mmol) in toluene (1 mL) was added tert-butyl bromoacetate (0.04 mL, 0.27 mmol), tetrabutylammonium hydrogensulfate (3 mg, 0.009 mmol) and powdered NaOH (32 mg, 0.81 mmol). The mixture was vigorously stirred at room temperature for 24 hours and was partitioned between EtOAc and H<sub>2</sub>O. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to afford crude compound **14b**. MS (CI) *m/z* 674.0 (MH<sup>+</sup>-Boc-tBu), 730.1 (MH<sup>+</sup>-Boc).

Step 14C: Preparation of 3-[(1-R-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-fluoro-3-([hydroxycarbonyl]methoxy-1-propoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione **14-1**

Compound **14b** in dichloromethane (3 mL) was treated with TFA (0.36 mL, 4.67 mmol) at room temperature overnight, concentrated and purified on prep TLC plate with 10% MeOH in DCM to afford compound **14-1** (60 mg, 49% over 2 steps). MS (CI) *m/z* 674.0 (MH<sup>+</sup>).


The following compounds were made according to the above procedure:



| No.  | R <sub>1a</sub> | R <sub>3</sub>  | Mass  | MW     | t <sub>R</sub><br>(method) |
|------|-----------------|-----------------|-------|--------|----------------------------|
| 14-1 | F               | CH <sub>3</sub> | 674.0 | 673.63 | 6.033 (6)                  |
| 14-2 | Cl              | H               | 676.1 | 676.06 | 22.40 (5)                  |

## Claims

1. A compound having the following structure:



or a stereoisomer, or pharmaceutically acceptable salt thereof,

wherein:

$R_{1a}$  and  $R_{1b}$  are the same or different and independently hydrogen, halogen, straight or branched  $C_{1-4}$ alkyl, or alkoxy;

$R_{2a}$  and  $R_{2b}$  are the same or different and independently hydrogen, halogen, trifluoromethyl, cyano or  $-SO_2CH_3$ ;

$R_3$  is hydrogen or methyl;

$R_4$  is phenyl, straight chain or branched  $C_{3-7}$ alkyl, or cyclic  $C_{3-7}$ alkyl;

$R_5$  and  $R_6$  are the same or different and independently hydrogen or straight or branched  $C_{1-4}$ alkyl; or

$R_5$  and the nitrogen to which it is attached taken together with  $R_4$  and the carbon to which it is attached form 1,2,3,4-tetrahydroisoquinoline or 2,3-dihydro-1H-isoinidole;

$R_7$  is  $-COOH$  or an acid isostere selected from the group consisting of tetrazole, 3H-[1,3,4]oxadiazol-2-one, [1,2,4]oxadiazol-3-one, 1,2-dihydro-[1,2,4]triazol-3-one, 2H-[1,2,4]oxadiazol-5-one, triazole substituted with a sulfonyl or sulfoxide group, imidazole substituted with a sulfonyl or sulfoxide group, [1,2,4]-oxadiazolidine-3,5-dione, [1,2,4]-thiadiazolidine-3,5-dione, imidazolidine-2,4-dione, imidazolidine-2,4,5-trione, pyrrolidine-2,5-dione and pyrrolidine-2,3,5-trione, -

$C(=O)NHSO_2NR_aR_b$ ,  $-C(=O)NHSO_2R_b$ ,  $-C(=O)NHC(=O)NR_aR_b$  or  $-C(=O)NHC(=O)R_b$ , where  $R_a$  is hydrogen or straight or branched  $C_{1-4}$ alkyl and  $R_b$  is straight or branched  $C_{1-4}$ alkyl; and

$X$  is  $-O-(C_{1-6}alkanediyI)$  or  $-O-(C_{1-6}alkanediyI)-O-(C_{1-6}alkanediyI)$  wherein each  $C_{1-6}alkanediyI$  is optionally substituted with from 1 to 3 straight or branched  $C_{1-4}$ alkyl groups.

2. The compound of claim 1 wherein  $R_{1a}$  is halogen.
3. The compound of claim 2 wherein  $R_{1a}$  is fluoro or chloro.
4. The compound of claim 1 wherein  $R_{1a}$  is hydrogen.
5. The compound of claim 1 wherein  $R_{2b}$  is halogen.
6. The compound of claim 1 wherein  $R_{2b}$  is trifluoromethyl, halogen or  $-SO_2CH_3$ .
7. The compound of claim 1 wherein  $R_3$  is hydrogen.
8. The compound of claim 1 wherein  $R_3$  is methyl.
9. The compound of claim 1 wherein  $R_4$  is phenyl.
10. The compound of claim 1 wherein  $R_4$  is cyclic  $C_{3-7}$ alkyl.
11. The compound of claim 10 wherein cyclic  $C_{3-7}$ alkyl is cyclopentyl or cyclohexyl.
12. The compound of claim 1 wherein  $R_5$  is H or methyl.
13. The compound of claim 1 wherein  $R_7$  is  $-COOH$ .

14. The compound of claim 1 wherein  $R_7$  is tetrazole, 3H-[1,3,4]oxadiazol-2-one, [1,2,4]oxadiazol-3-one, 1,2-dihydro-[1,2,4]triazol-3-one, 2H-[1,2,4]oxadiazol-5-one, triazole substituted with a sulfonyl or sulfoxide group, imidazole substituted with a sulfonyl or sulfoxide group, [1,2,4]-oxadiazolidine-3,5-dione, [1,2,4]-thiadiazolidine-3,5-dione, imidazolidine-2,4-dione, imidazolidine-2,4,5-trione, pyrrolidine-2,5-dione and pyrrolidine-2,3,5-trione,  $-C(=O)NHSO_2NR_aR_b$ ,  $-C(=O)NHSO_2R_b$ ,  $-C(=O)NHC(=O)NR_aR_b$  or  $-C(=O)NHC(=O)R_b$ , where  $R_a$  is hydrogen or straight or branched  $C_{1-4}$ alkyl and  $R_b$  is straight or branched  $C_{1-4}$ alkyl.

15. The compound of claim 1 wherein  $C_{1-6}$ alkanediyl is straight chain  $C_{1-6}$ alkanediyl.

16. The compound of claim 15 wherein the straight chain  $C_{1-6}$ alkanediyl is  $-CH_2CH_2CH_2-$ .

17. The compound of claim 15 wherein the straight chain  $C_{1-6}$ alkanediyl is  $-CH_2CH_2CH_2CH_2-$ .

18. The compound of claim 15 wherein the straight chain  $C_{1-6}$ alkanediyl is  $-CH_2CH_2CH_2CH_2CH_2-$ .

19. The compound of 1 wherein  $C_{1-6}$ alkanediyl is branched  $C_{1-6}$ alkanediyl.

20. The compound of claim 1 wherein the compound is 3-[2(R)-amino-2-phenylethyl]-5-(2-fluoro-3-([4-hydroxycarbonyl]-1-butoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione, 3-[2(R)-amino-2-phenylethyl]-5-(3-([5-hydroxycarbonyl]-1-pentoxy)phenyl)-1-[2-fluoro-6-chlorobenzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione, 3-[2(R)-amino-2-phenylethyl]-5-(3-([5-hydroxycarbonyl]-1-pentoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione, 3-[2(R)-methylamino-2-phenylethyl]-5-(2-fluoro-3-([4-hydroxycarbonyl]-1-butoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione, 3-[(1-*R*-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(3-([5-hydroxycarbonyl]-1-pentoxy)phenyl)-1-[2-fluoro-6-

(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione, 3-[(1-*R*-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-fluoro-3-([4-hydroxycarbonyl]-1-butoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione, 3-[(1-*R*-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-fluoro-3-([3-hydroxycarbonyl]-1-propoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-pyrimidine-2,4(1*H*,3*H*)-dione, 3-[(1-*R*-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-chloro-3-([4-hydroxycarbonyl]-1-butoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-pyrimidine-2,4(1*H*,3*H*)-dione or 3-[(1-*R*-1,2,3,4-tetrahydroisoquinoline)methyl]-5-(2-chloro-3-([5-hydroxycarbonyl]-1-pentoxy)phenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-pyrimidine-2,4(1*H*,3*H*)-dione.

21. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

22. Use of the compound according to claim 1 for preparing a medicament for the treatment of a disease responsive to antagonizing gonadotropin-releasing hormone.

23. Use of the pharmaceutical composition according to claim 21 for preparing a medicament for treating a sex-hormone related condition.


24. The use of claim 23 wherein the sex-hormone related condition is cancer, benign prostatic hypertrophy or myoma of the uterus.

25. The use of claim 24 wherein the cancer is prostatic cancer, uterine cancer, breast cancer or pituitary gonadotroph adenomas.

26. The use of claim 25 wherein the cancer is prostatic cancer.

27. The use of claim 23 wherein the sex-hormone related condition is endometriosis, polycystic ovarian disease, uterine fibroids or precocious puberty.

28. The use of claim 27 wherein the sex-hormone related condition is endometriosis.
29. The use of claim 23 wherein the sex-hormone related condition is uterine fibroids.
30. Use of the pharmaceutical composition according to claim 21 for preparing a medicament for treating infertility.
31. Use of the pharmaceutical composition according to claim 21 for preparing a medicament for treating lupus erythematosus, irritable bowel syndrome, premenstrual syndrome, hirsutism, short stature or sleep disorders.



(I)